Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/16—Purine radicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4192—1,2,3-Triazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
  • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7135—Compounds containing heavy metals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/545—Heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
  • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
  • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
  • A61K51/04—Organic compounds
  • A61K51/041—Heterocyclic compounds
  • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
  • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P33/00—Antiparasitic agents
  • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
  • A61P33/06—Antimalarials
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
  • C07D323/02—Five-membered rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
  • C07D471/14—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/10—Spiro-condensed systems
  • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/10—Spiro-condensed systems
  • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
  • C07D491/14—Ortho-condensed systems
  • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
  • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
  • C07D493/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
  • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
  • C07D493/14—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
  • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/08—Compounds having one or more C—Si linkages
  • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
  • C07F7/1804—Compounds having Si-O-C linkages
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
  • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
  • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
  • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/06—Pyrimidine radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
  • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
  • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
  • C07H19/16—Purine radicals
  • C07H19/167—Purine radicals with ribosyl as the saccharide radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/05—Isotopically modified compounds, e.g. labelled
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• chemotherapeutic agents used to treat cancer exhibit serious toxicity, resulting in undesired side effects for patients and reducing efficacy by limiting the doses that can be safely administered.
• many of the therapeutics used to treat infectious diseases, including parasitic diseases confer undesirable side effects. It would be preferable if such agents could be administered in a prodrug form that masked the inherent toxicity of the agent from irrelevant, non-diseased tissues, and yet released the fully active drug species at the desired site of action.
• Such a technology would have the potential to increase the therapeutic window of a variety of drugs, possibly allowing them to be used safely at a more efficacious dose, and with reduced incidence of undesired side-effects for the patient.
• iron In normal cells and tissues, iron remains sequestered in forms that are non-toxic to the cell, bound to the iron carrying protein transferrin for example, or bound as heme within hemoglobin.
• Diseased tissues and cells can contain higher than normal concentrations of iron.
• Many neoplastic cells for example over-express the transferrin receptor to increase their uptake of iron. Increased iron uptake has been proposed to explain the increased toxicity that iron-dependent endoperoxides like artemisinin exhibit towards cancer cell lines as compared to normal cells (Efferth, T. Drug Resistance Updates, 2005, 8:85-97).
• the expression level of the transferrin receptor was shown to correlate with the cytotoxicity of an artemisinin derivative towards HeLa cells (see for example Disbrow, G. L., et al Cancer Research, 2005, 65, 10854-10861). Artemisinin and its derivatives are believed to exert their cytotoxic effect via reaction with Fe and the resulting generation of reactive oxygen and carbon centered radical species.
• the cytotoxicity of artemisinin derivatives towards leukemia, astrocytoma, and breast cancer cell lines can be potentiated by the addition of exogenous Fe 11 salts or transferrin (Efferth, T. et al Free Radical Biology & Medicine, 2004, 37, 998-1009; Singh, N. P.
• a cytotoxic agent to a targeting moiety such as a protein or antibody via an acid-labile linker moiety
• a targeting moiety such as a protein or antibody via an acid-labile linker moiety
• Acid labile linker moieties have also been used to attach drug species to biopolymers or antibodies where the intention is that the lower pH of the diseased tissue serves to trigger release of the drug moiety.
• ADC Antibody-drug conjugates
• ADC are currently being developed for the more selective delivery of therapeutic agents, especially in cancer.
• a potent drug is conjugated to an antibody that recognizes antigen on a particular cell type of interest.
• the ADC is internalized via receptor mediated endocytosis and the free drug is released, often via an acid labile linker or a reductively labile (disulfide) linker.
• ADCs are complex and not always as selective as desired because the targeted antigen can be expressed in normal cells. Insufficiently stable linkers can also result in spurious drug release from ADCs. Disclosed herein, inter alia, are solutions to these and other problems in the art.
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are independently hydrogen, oxo, halogen,
• a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound described herein (including in an aspect, embodiment, table, example, or claim), or pharmaceutically acceptable salt thereof.
• a method of treating a disease in a patient in need of such treatment including administering a therapeutically effective amount of a compound described herein (including in an aspect, embodiment, table, example, or claim), or a pharmaceutically acceptable salt thereof, to the patient.
• a method of identifying a patient having a disease associated with a cell or organism having an increased Fe 11 level compared to a standard control including administering an effective amount of a compound described herein (including in an aspect, embodiment, table, example, or claim), or a pharmaceutically acceptable salt thereof, to the patient.
• Fig. 1 In vivo efficacy of Example 23 (9.5 mg/kg/day, solid line) as compared to chloroquine (33 mg/kg/day, dashed line) and arterolane tosylate (13.6 mg/kg/day, dotted line) in P. berghei infected mice. All compounds were administered to P. berghei infected mice by oral gavage once a day for three days at the indicated daily dose. DETAILED DESCRIPTION OF THE INVENTION
• Described hererin are novel prodrugs capable of the selective release of an agent (e.g. drug, detectable agent, protein) to biological compartments containing unbound forms of ferrous iron, pharmaceutical compositions thereof, methods for their use, and methods for preparing these prodrugs.
• an agent e.g. drug, detectable agent, protein
• Described herein is the use of the prodrugs in the treatment of parasitic and neoplastic disease, or any condition where the targeting of cells or biological compartments with higher than normal concentrations of a reductant (e.g. ferrous iron) is of benefit (e.g. diagnostic or therapeutic).
• a reductant e.g. ferrous iron
• Examples of the prodrug moieties described herein include a heterocyclic ring system containing a peroxide bond (e.g.
• the agent e.g. drug, detectable agent, protein
• the agent may be directly embedded in the structure of the prodrug, or it may be attached via a self-immolating linker.
• the peroxide containing heterocyclic undergoes a fragmentation reaction, releasing the agent (e.g. drug, detectable agent, protein), or alternatively unveiling a carbonyl function in the linker, which then undergoes a spontaneous elimination reaction to release the tethered agent (e.g. drug, detectable agent, protein).
• the agent e.g. drug, detectable agent, protein
• alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched non-cyclic carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e., Ci-Cio means one to ten carbons).
• saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec -butyl,
• an unsaturated alkyl group is one having one or more double bonds or triple bonds.
• unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2- isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3- butynyl, and the higher homologs and isomers.
• alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-0-).
• alkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited
• alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention.
• a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
• alkenylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.
• heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched non-cyclic chain, or combinations thereof, including at least one carbon atom and at least one heteroatom selected from the group consisting of O, N, P, Si, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
• the heteroatom(s) O, N, P, S, and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule.
• heteroalkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH 2 -CH 2 -S-CH 2 -CH 2 - and -CH 2 -S-CH 2 -CH 2 -NH-CH 2 -.
• heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy,
• heteroalkyl groups include those groups that are attached to the remainder of the molecule through a heteroatom, such as -C(0)R', -C(0)NR, -NR'R", -OR, -SR', and/or -S0 2 R.
• heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as -NR'R" or the like, it will be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive.
• heteroalkyl should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR'R" or the like.
• cycloalkyl and “heterocycloalkyl,” by themselves or in combination with other terms, mean, unless otherwise stated, non-aromatic cyclic versions of “alkyl” and
• heteroalkyl respectively, wherein the carbons making up the ring or rings do not necessarily need to be bonded to a hydrogen due to all carbon valencies participating in bonds with non- hydrogen atoms. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule.
• cycloalkyl examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, 3-hydroxy-cyclobut-3-enyl-l,2, dione, lH-l,2,4-triazolyl-5(4H)- one, 4H-l,2,4-triazolyl, and the like.
• heterocycloalkyl examples include, but are not limited to, l-(l,2,5,6-tetrahydropyridyl), 1 -piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3- morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3- yl, 1-piperazinyl, 2-piperazinyl, and the like.
• a "cycloalkylene” and a "heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.
• halo or halogen
• haloalkyl by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
• terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl.
• halo(Ci-C4)alkyl includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
• acyl means, unless otherwise stated, -C(0)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
• aryl means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently.
• a fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring.
• heteroaryl refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
• heteroaryl includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring).
• a 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
• a 6,6- fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
• a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring.
• a heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom.
• Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1- pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2- thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4- pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1- is
• aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
• Non-limiting examples of aryl and heteroaryl groups include pyridinyl, pyrimidinyl, thiophenyl, thienyl, furanyl, indolyl, benzoxadiazolyl, benzodioxolyl,
• a fused ring heterocyloalkyl-aryl is an aryl fused to a heterocycloalkyl.
• a fused ring heterocycloalkyl-heteroaryl is a heteroaryl fused to a heterocycloalkyl.
• heterocycloalkyl-cycloalkyl is a heterocycloalkyl fused to a cycloalkyl.
• heterocycloalkyl-heterocycloalkyl is a heterocycloalkyl fused to another heterocycloalkyl.
• Fused ring heterocycloalkyl-aryl, fused ring heterocycloalkyl-heteroaryl, fused ring heterocycloalkyl- cycloalkyl, or fused ring heterocycloalkyl-heterocycloalkyl may each independently be unsubstituted or substituted with one or more of the substitutents described herein.
• oxo as used herein, means an oxygen that is double bonded to a carbon atom.
• alkylsulfonyl means a moiety having the formula -S(02)-R', where R' is a substituted or unsubstituted alkyl group as defined above. R' may have a specified number of carbons (e.g., "C 1 -C 4 alkylsulfonyl").
• -NR'C (0)NR"NR"'R"", -CN, -N0 2 , in a number ranging from zero to (2m'+l), where m' is the total number of carbon atoms in such radical.
• R, R, R", R", and R"" each preferably
• each of the R groups is independently selected as are each R', R", R", and R"" group when more than one of these groups is present.
• R and R" When R and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring.
• -NR'R includes, but is not limited to, 1 -pyrrolidinyl and 4-morpholinyl.
• alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF 3 and -CH 2 CF 3 ) and acyl (e.g., -C(0)CH 3 , -C(0)CF 3 , -C(0)CH 2 OCH 3 , and the like).
• R', R", R', and R" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
• each of the R groups is independently selected as are each R', R", R'", and R"" groups when more than
• Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups.
• Such so-called ring- forming substituents are typically, though not necessarily, found attached to a cyclic base structure.
• the ring-forming substituents are attached to adjacent members of the base structure.
• two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure.
• the ring-forming substituents are attached to a single member of the base structure.
• two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure.
• the ring- forming substituents are attached to non-adjacent members of the base structure.
• Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(0)-(CRR') q -U-, wherein T and U are
• q is an integer of from 0 to 3.
• two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r -B-, wherein A and B are independently -CRR'-, -0-, -NR-, -S-, -S(O) -, -S(0) 2 -, -S(0) 2 NR'-, or a single bond, and r is an integer of from 1 to 4.
• One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
• two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the
• R, R, R", and R" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
• heteroatom or "ring heteroatom” are meant to include, oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
• a "substituent group,” as used herein, means a group selected from the following moieties:
• heterocycloalkyl unsubstituted aryl, unsubstituted heteroaryl, and
• heterocycloalkyl unsubstituted aryl, unsubstituted heteroaryl.
• a "size-limited substituent” or " size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a "substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-C 2 o alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C 10 aryl, and each substituted or unsubstituted heteroaryl is
• a "lower substituent” or " lower substituent group,” as used herein, means a group selected from all of the substituents described above for a "substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted Q-Cg alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C 10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or
• each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In other embodiments, at least one or all of these groups are substituted with at least one lower substituent group.
• each substituted or unsubstituted alkyl may be a substituted or unsubstituted C1-C2 0 alkyl
• each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl
• each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl
• each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl
• each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C1 0 aryl
• each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.
• each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C2 0 alkylene
• each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene
• each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C8 cycloalkylene
• each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene
• each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C1 0 arylene
• each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.
• each substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-Cs alkyl
• each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl
• each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl
• each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl
• each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C1 0 aryl
• each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.
• each substituted or unsubstituted alkylene is a substituted or unsubstituted Ci-Cs alkylene
• each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene
• each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C7 cycloalkylene
• each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene
• each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C1 0 arylene
• each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene.
• the compound is a chemical species set forth in the Examples section, figures, or tables below.
• pharmaceutically acceptable salts is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
• base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
• pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
• acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
• suitable inert solvent examples include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric,
• salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, e.g., Berge et ah, Journal of Pharmaceutical Science 66: 1-19 (1977)).
• Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
• Other pharmaceutically acceptable carriers known to those of skill in the art are suitable for the present invention. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.
• the preparation may be a lyophilized powder in 1 mM-50 mM histidine, 0. l%-2% sucrose, 2%-7% mannitol at a pH ranee of 4.5 to 5.5, that is combined with buffer prior to use.
• the compounds of the present invention may exist as salts, such as with
• the present invention includes such salts.
• salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, (-)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid.
• These salts may be prepared by methods known to those skilled in the art.
• the neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
• the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
• agents e.g. compounds, proteins, drugs, detectable agents, therapeutic agents
• Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under select physiological conditions (e.g. increased Fe 11 concentration relative to normal physiological levels, increased reductant levels relative to normal physiological levels) to provide the final agents (e.g. compounds, proteins, drugs, detectable agents, therapeutic agents). Additionally, prodrugs can be converted to agents (e.g. compounds, proteins, drugs, detectable agents, therapeutic agents) by chemical or biochemical methods in an ex vivo environment. Prodrugs described herein include compounds that readily undergo chemical changes under select physiological conditions (e.g.
• agents e.g. compounds, proteins, drugs, detectable agents, therapeutic agents
• a biological system e.g. in a subject, in an infected cell, in a cancer cell, in the extracellular space near an infected cell, in the extracellular space near a cancer cell from the moieties (e.g. moiety of a protein, drug, detectable agent) attached to the prodrug moiety and included in the prodrug (e.g. compound of formula I, including embodiments, compound described herein, examples)).
• Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
• salt refers to acid or base salts of the compounds used in the methods of the present invention.
• Illustrative examples of acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts.
• Certain compounds of the present invention possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present invention.
• the compounds of the present invention do not include those which are known in art to be too unstable to synthesize and/or isolate.
• the present invention is meant to include compounds in racemic and optically pure forms.
• Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
• the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
• isomers refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.
• tautomer refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.
• structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
• compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by C- or C-enriched carbon are within the scope of this invention.
• the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
• the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine- 125 ( 125 I), or carbon- 14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
• substituted with a[n] means the specified group may be substituted with one or more of any or all of the named substituents.
• a group such as an alkyl or heteroaryl group, is "substituted with an unsubstituted C1-C2 0 alkyl, or unsubstituted 2 to 20 membered heteroalkyl,” the group may contain one or more unsubstituted C1-C20 alkyls, and/or one or more unsubstituted 2 to 20 membered heteroalkyls.
• R-substituted where a moiety is substituted with an R substituent, the group may be referred to as "R-substituted.” Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different.
• polypeptide refers to a polymer of amino acid residues.
• the terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
• the terms encompass amino acid chains of any length, including full length proteins (i.e., antigens), wherein the amino acid residues are linked by covalent peptide bonds.
• a protein moiety is a radical of a protein.
• peptidyl and "peptidyl moiety” means a monovalent peptide.
• amino acid refers to naturally occurring and synthetic amino acids, as well as amino acid analogs.
• Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, ⁇ -carboxyglutamate, and O-phosphoserine.
• Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an a-carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups
• Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.
• An oligomer comprising amino acid mimetics is a peptidomimetic.
• a peptidomimetic moiety is a monovalent peptidomimetic.
• Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical
• amino acid or nucleotide base "position" is denoted by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5'-end). Due to deletions, insertions, truncations, fusions, and the like that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence determined by simply counting from the N- terminus will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where a variant has a deletion relative to an aligned reference sequence, there will be no amino acid in the variant that corresponds to a position in the reference sequence at the site of deletion.
• a “conservative substitution” as used with respect to amino acids refers to the substitution of an amino acid with a chemically similar amino acid.
• Amino acid substitutions which often preserve the structural and/or functional properties of the polypeptide in which the substitution is made are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, in “The Proteins,” Academic Press, New York.
• the most commonly occurring exchanges are isoleucine/valine, tyrosine/phenylalanine, aspartic acid/glutamic acid, lysine/arginine, methionine/leucine, aspartic acid/asparagine, glutamic acid/glutamine, leucine/isoleucine, methionine/isoleucine, threonine/serine, tryptophan/phenylalanine, tyrosine/histidine, tyrosine/tryptophan, glutamine/arginine, histidine/asparagine,
• phenylalanine/leucine phenylalanine/methionine, serine/alanine, serine/asparagine,
• valine/leucine valine/leucine
• valine/methionine valine/methionine
• the following eight groups each contain amino acids that are conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).
• isolated refers to a nucleic acid, polynucleotide, polypeptide, protein, or other component that is partially or completely separated from components with which it is normally associated (other proteins, nucleic acids, cells, etc.).
• an isolated polypeptide or protein is a recombinant polypeptide or protein.
• antibody refers to a polypeptide encoded by an immunoglobulin gene or functional fragments thereof that specifically binds and recognizes an antigen.
• the recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes.
• Light chains are classified as either kappa or lambda.
• Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.
• An antibody moiety is a radical of an antibody.
• Non-limiting examples of antibodies (or functional fragments thereof or antigen-binding fragments thereof, derived from such antibodies) that may be included in the compounds described herein include 3F8, 8H9, Abagovomab, Abciximab, Abrilumab, Actoxumab, Adalimumab, Adecatumumab, Aducanumab, Afelimomab, Afutuzumab, Alacizumab pegol, ALD518, Alemtuzumab, Alirocumab,
• Altumomab pentetate Amatuximab, Anatumomab mafenatox, Anifrolumab, Anrukinzumab (IMA-638), Apolizumab, Arcitumomab, Aselizumab, Atinumab, Atlizumab (tocilizumab), Atorolimumab, Bapineuzumab, Basiliximab, Bavituximab, Bectumomab, Belimumab,
• Bimagrumab Bivatuzumab mertansine, Blinatumomab, Blosozumab, Brentuximab vedotin, Briakinumab, Brodalumab, Canakinumab, Cantuzumab mertansine, Cantuzumab ravtansine, Caplacizumab, Capromab pendetide, Carlumab, Catumaxomab, CC49, cBR96-doxorubicin immunoconjugate, Cedelizumab, Certolizumab pegol, Cetuximab, Ch.14.18, Citatuzumab communicatingox, Cixutumumab, Clazakizumab, Clenoliximab, Clivatuzumab tetraxetan, Conatumumab, Concizumab, Crenezumab, CR6261, Dacetuzumab, Daclizumab, Dalot
• Drozitumab Duligotumab, Dupilumab, Durvalumab, Dusigitumab, Ecromeximab, Eculizumab, Edobacomab, Edrecolomab, Efalizumab, Efungumab, Eldelumab, Elotuzumab, Elsilimomab, Emibetuzumab, Enavatuzumab, Enfortumab vedotin, Enlimomab pegol, Enokizumab,
• Enoticumab Ensituximab, Epitumomab cituxetan, Epratuzumab, Erlizumab, Ertumaxomab, Etaracizumab, Etrolizumab, Evinacumab, Evolocumab, Exbivirumab, Fanolesomab,
• Faralimomab Farletuzumab, Fasinumab, FBTA05 , Felvizumab, Fezakinumab, Ficlatuzumab, Figitumumab, Flanvotumab, Fletikumab, Fontolizumab, Foralumab, Foravirumab,
• Intetumumab Inolimomab, Inotuzumab ozogamicin, Ipilimumab, Iratumumab, Itolizumab, Ixekizumab, Keliximab, Labetuzumab, Lambrolizumab, Lampalizumab, Lebrikizumab,
• Olaratumab Olokizumab, Omalizumab, Onartuzumab, Ontuxizumab, Oportuzumab monatox, Oregovomab, Orticumab, Otelixizumab, Otlertuzumab, Oxelumab, Ozanezumab, Ozoralizumab, Pagibaximab, Palivizumab, Panitumumab, Pankomab, Panobacumab, Parsatuzumab,
• Pascolizumab Pateclizumab, Patritumab, Pembrolizumab, Pemtumomab, Perakizumab, Pertuzumab, Pexelizumab, Pidilizumab, Pinatuzumab vedotin, Pintumomab, Placulumab, Polatuzumab vedotin , Ponezumab, Priliximab, Pritoxaximab, Pritumumab, PRO 140,
• Raxibacumab Regavirumab, Reslizumab, Rilotumumab, Rituximab, Robatumumab,
• Roledumab Romosozumab, Rontalizumab, Rovelizumab, Ruplizumab, Samalizumab,
• Talizumab Tanezumab, Taplitumomab paptox, Tarextumab, Tefibazumab, Telimomab aritox, Tenatumomab, Teneliximab, Teplizumab, Teprotumumab, TGN1412, Ticilimumab
• Tildrakizumab Tildrakizumab
• Tigatuzumab Tigatuzumab
• TNX-650 Tocilizumab (atlizumab)
• Toralizumab Tositumomab, Tovetumab, Tralokinumab, Trastuzumab, TRBS07, Tregalizumab, Tremelimumab, Tucotuzumab celmoleukin, Tuvirumab, Ublituximab, Urelumab, Urtoxazumab, Ustekinumab, Vantictumab, Vapaliximab, Varlilumab, Vatelizumab, Vedolizumab, Veltuzumab, Vepalimomab, Vesencumab, Visilizumab, Volociximab, Vorsetuzumab mafodotin, Votumumab, Zalutumumab, Zanolimumab, Zatuximab, Ziralimumab, and Zolimomab aritox.
• An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light"
• variable heavy chain refers to the variable region of an immunoglobulin heavy chain, including an Fv, scFv , dsFv or Fab; while the terms “variable light chain,” “VL” or “VL” refer to the variable region of an immunoglobulin light chain, including of an Fv, scFv , dsFv or Fab.
• antibody functional fragments include, but are not limited to, complete antibody molecules, antibody fragments, such as Fv, single chain Fv (scFv), complementarity determining regions (CDRs), VL (light chain variable region), VH (heavy chain variable region), Fab, F(ab)2' and any combination of those or any other functional portion of an immunoglobulin peptide capable of binding to target antigen (see, e.g., Fv, single chain Fv (scFv), complementarity determining regions (CDRs), VL (light chain variable region), VH (heavy chain variable region), Fab, F(ab)2' and any combination of those or any other functional portion of an immunoglobulin peptide capable of binding to target antigen (see, e.g., Fv, single chain Fv (scFv), complementarity determining regions (CDRs), VL (light chain variable region), VH (heavy chain variable region), Fab, F(ab)2' and any combination of those or any other functional
• antibody fragments can be obtained by a variety of methods, for example, digestion of an intact antibody with an enzyme, such as pepsin; or de novo synthesis. Antibody fragments are often synthesized de novo either chemically or by using recombinant DNA methodology.
• the term antibody includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al, (1990) Nature 348:552).
• antibody also includes bivalent or bispecific molecules, diabodies, triabodies, and tetrabodies.
• Bivalent and bispecific molecules are described in, e.g., Kostelny et al. (1992) J. Immunol. 148: 1547, Pack and Pluckthun (1992) Biochemistry 31 : 1579, Hollinger et al.( 1993), PNAS. USA 90:6444, Gruber et al. (1994) J Immunol. 152:5368, Z m et al. (1997) Protein Sci. 6:781, Hu et al. (1996) Cancer Res. 56:3055, Adams et al. (1993) Cancer Res. 53 :4026, and McCartney, et al. (1995) Protein Eng. 8:301.
• a “label” or a “detectable agent” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, magnetic resonance imaging, or other physical means.
• useful detectable agents include 32 P, fluorescent dyes, electron- dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, paramagnetic molecules, paramagnetic nanoparticles, ultrasmall superparamagnetic iron oxide (“USPIO”) nanoparticles, USPIO nanoparticle aggregates, nanoparticle contrast agents, liposomes or other delivery vehicles containing Gadolinium chelate (“Gd-chelate”) molecules, Gadolinium, radioisotopes, radionuclides (e.g.
• fluorine-18 labeled fluorodeoxyglucose nucleotide or nucleoside
• fluorine-18 labeled A, C, G, or T fluorine-18 labeled A, C, G, or T
• gamma ray emitting radionuclides positron- emitting radionuclide
• radiolabeled glucose radiolabeled water
• radiolabeled ammonia biocolloids
• microbubbles e.g.
• microbubble shells including albumin, galactose, lipid, and/or polymers
• microbubble gas core including air, heavy gas(es), perfluorcarbon, nitrogen, octafluoropropane, perflexane lipid microsphere, perflutren, etc.
• iodinated contrast agents e.g.
• iohexol iodixanol, ioversol, iopamidol, ioxilan, iopromide, diatrizoate, metrizoate, ioxaglate), barium sulfate, thorium dioxide, gold, gold nanoparticles, gold nanoparticle aggregates, fluorophores, two-photon fluorophores, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into a peptide or antibody specifically reactive with a target peptide.
• Detectable agents also include any of the above compositions encapsulated in nanoparticles, particles, aggregates, coated with additional compositions, derivatized for binding to a targeting agent (e.g. antibody or antigen binding fragment).
• a detectable moiety is a radical of a detectable agent.
• fluorophore or “fluorescent agent” are used interchangeably and refer to a composition (e.g. compound) that can absorb light at one or more wavelenghs and re-emit light at one or more longer wavelengths, relative to the one or more wavelengths of absorbed light.
• fluorophores that may be included in the compositions described herein include fluorescent proteins, xanthene derivatives (e.g. fluorescein, rhodamine, Oregon green, eosin, or Texas red), cyanine and derivatives (e.g.
• cyanine indocarbocyanine, oxacarbocyanine, thiacarbocyanine or merocyanine
• napththalene derivatives e.g. dansyl or prodan derivatives
• coumarin and derivatives oxadiazole derivatives (e.g. pyridyloxazole, nitrobenzoxadiazole or benzoxadiazole), anthracene derivatives (e.g. anthraquinones, DRAQ5, DRAQ7, or CyTRAK Orange), , pyrene derivatives (e.g. cascade blue and derivatives), oxazine derivatives (e.g.
• Nile red, Nile blue, cresyl violet, oxazine 170 Nile red, Nile blue, cresyl violet, oxazine 170
• acridine derivatives e.g. pro flavin, acridine orange, acridine yellow
• arylmethine derivatives e.g. auramine, crystal violet, malachite green
• tetrapyrrole derivatives e.g. porphin, phthalocyanine, bilirubin
• CF dyeTM, DRAQTM acridine derivatives
• acridine derivatives e.g. pro flavin, acridine orange, acridine yellow
• arylmethine derivatives e.g. auramine, crystal violet, malachite green
• tetrapyrrole derivatives e.g. porphin, phthalocyanine, bilirubin
• CF dyeTM DRAQTM
• CyTRAKTM BODIPYTM, Alexa FluorTM, DyLight FluorTM, AttoTM, TracyTM, FluoProbesTM, Abberior DyesTM, DYTM dyes, MegaStokes DyesTM, Sulfo CyTM, SetaTM dyes, SeTauTM dyes, Square DyesTM, QuasarTM dyes, Cal FluorTM dyes, SureLight DyesTM, PerCPTM,
• a fluorescent moiety is a radical of a fluorescent agent.
• drug is used in accordance with its common meaning and refers to a substance which has a physiological effect (e.g. beneficial effect, is useful for treating a subject) when introduced into or to a subject (e.g. in or on the body of a subject or patient).
• a drug moiety is a radical of a drug.
• siderophore is used in accordance with its common meaning and refers to a high-affinity iron chelating compound that may be secreted by a microorganism (e.g., bacteria, fun si. grasses!
• a microorganism e.g., bacteria, fun si. grasses!
• Non-limiting examples of siderophores include catecholates (e.g., phenolates), hydroxamates, carboxylates (e.g., derivatives of citric acid), ferrichrome, desfemoxamine B (deferoxamine), desfemoxamine E, fusarinine C, ornibactin, rhodotorulic acid, enterobactin, bacillibactin, vibriobactin, azotobactin, pyoverdine, yersiniabactin, aerobactin, slmochelin, alcaligin, mycobactin, stapliyloferrin A, and petrobactin.
• catecholates e.g., phenolates
• hydroxamates e.g., carboxylates (e.g., derivatives of citric acid)
• ferrichrome e.g., desfemoxamine B (deferoxamine), desfem
• a siderophore may chelate a non-iron metal (e.g., aluminum, gallium, chromium, copper, zinc, lead, manganese, cadmium vanadium indium, plutonium, or uranium).
• sideropohore moiety is a radical of a siderophore.
• Additional non-limiting examples of a siderophore include Achromobactin, Acinetobactin, Acinetoferrin, Aerobactin, Aeruginic, Agrobactin, Agrobactin A, Albomycin 271, Alcaligin 230, Alterobactin A, Alterobactin B, Aminochelin 262, Amonabactin P693,
• Desfemoxamine Etl 21A Desfemoxamine Et2 21B, Desfemoxamine Et3 21C,
• Desfemoxamine Gl Desfemoxamine G2A, Desfemoxamine G2B, Desfemoxamine G2C, Desfemoxamine H, Desfemoxamine PI, Desfemoxamine Tl, Desfemoxamine T2,
• Ferrimycin A Ferrirhodin, Ferrirubin, Ferrocin A, Fluvibactin, Formobactin, Fusarinine A, Fusarinine B, Fusarinine C, Heterobactin A, Heterobactin B, Hydroxycopropen,
• Hydroxyisoneocoprogen I 3-Hydroxymugineic acid, 5, Hydroxy-neocoprogen I, Isoneocoprogen I, Isopyoverdin BTP1, Isopyoverdin 6.7, Isopyoverdin 7.13, Isopyoverdin 90- 33, Isopyoverdin 90-44, Isopyoverdin 10.7, Isotriornicin, Itoic acid, Loihichelin A, Loihichelin B, Loihichelin C, Loihichelin D, Loihichelin E, Loihichelin F, Maduraferrin, Malonichrome, Marinobactin A, Marinobactin B, Marinobactin C, Marinobactin Dl, Marinobactin D2, Marinobactin E, Micacocidin, Mugineic acid, Mycobactin A, Mycobactin Av, Mycobactin F, Myco
• Tetraglycine ferrichrome Tetraglycine ferrichrome, Thiazostatin, Triacetylfusarinine, Triornicin, Vibriobactin,
• Treating refers to any indicia of success in the treatment or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being.
• the treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation.
• certain methods herein treat cancer.
• certain methods herein treat cancer by decreasing a symptom of cancer. Symptoms of cancer would be known or may be determined by a person of ordinary skill in the art.
• treating and conjugations thereof include prevention of an injury, pathology, condition, or disease.
• infectious diseases e.g., malaria, bacterial diseases, viral diseases, parasitic diseases.
• infectious diseases e.g., malaria, bacterial diseases, viral diseases, parasitic diseases
• infectious diseases e.g., malaria, bacterial diseases, viral diseases, parasitic diseases
• a symptom of the infectious disease e.g., malaria, bacterial diseases, viral diseases, parasitic diseases
• certain methods herein treat infectious diseases (e.g., malaria, bacterial diseases, viral diseases, parasitic diseases) by decreasing the level or viability or amount of the infectious agent (e.g., bacterium, virus, parasite).
• an "effective amount” is an amount sufficient to accomplish a stated purpose (e.g.
• an "effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a "therapeutically effective amount.”
• a “reduction” of a symptom or symptoms means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s).
• a “prophylactically effective amount" of a drug or prodrug is an amount of a drug or prodrug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms.
• the full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses.
• a prophylactically effective amount may be administered in one or more administrations.
• cancer is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function.
• a disease associated with an infectious organism may be treated with an agent (e.g. compound as described herein) effective for decreasing the amount of the infectious organism.
• Control or "control experiment” or “standard control” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects.
• Contacting is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including
• contacting may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a protein or enzyme. In some embodiments contacting includes allowing a compound described herein to interact with a protein or enzyme.
• inhibition means negatively affecting (e.g. decreasing) the level of activity or function of the protein relative to the level of activity or function of the protein in the absence of the inhibitor.
• inhibition refers to reduction of a disease or symptoms of disease.
• inhibition may include, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating signal transduction or enzymatic activity or the amount of a protein.
• activation means positively affecting (e.g.
• activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease.
• activation may include, at least in part, partially or totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up- regulating signal transduction or enzymatic activity or the amount of a protein.
• modulator refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule.
• a modulator is an anticancer agent.
• a modulator is an anti-infective agent.
• a modulator is an anti-malarial agent.
• Anti-cancer agent or "anti-cancer drug” is used in accordance with its plain ordinary meaning and refers to a composition (e.g. compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells.
• an anti-cancer agent is a chemotherapeutic.
• an anti- cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer.
• an anti-cancer agent is an agent with antineoplastic properties that has not (e.g., yet) been approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer.
• anti-cancer agents include, but are not limited to, MEK (e.g. MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g. XL518, CI-1040, PD035901, selumetinib/ AZD6244, GSK1120212/ trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), e
• folic acid analog e.g., methotrexate
• pyrimidine analogs e.g., fluorouracil, floxouridine, Cytarabine
• purine analogs e.g., mercaptopurine, thioguanine, pentostatin
• plant alkaloids e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.
• topoisomerase inhibitors e.g., irinotecan, topotecan, amsacrine, etoposide (VP 16), etoposide phosphate, teniposide, etc.
• antitumor antibiotics e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mito
• fluorodaunorunicin hydrochloride gadolinium texaphyrin; gallium nitrate; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; immunostimulant peptides; insulin-like growth factor- 1 receptor inhibitor; interferon agonists; interferons; interleukins; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; matrilysin inhibitors; matrix metalloproteinase inhibitors; MIF inhibitor; mifepristone;
• mismatched double stranded RNA monoclonal antibody,; mycobacterial cell wall extract; nitric oxide modulators; oxaliplatin; panomifene; pentrozole; phosphatase inhibitors; plasminogen activator inhibitor; platinum complex; platinum compounds; prednisone; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; ribozymes; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; stem cell inhibitor; stem-cell division inhibitors; stromelysin inhibitors; synthetic glycosaminoglycans; tamoxifen methiodide;
• telomerase inhibitors thyroid stimulating hormone; translation inhibitors; tyrosine kinase inhibitors; urokinase receptor antagonists; steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate,
• GnRH gonadotropin-releasing hormone agonists
• adrenocorticosteroids e.g., prednisone
• fluoxymesterone e.g., flutamide
• immunostimulants e.g., Bacillus Calmette- Guerin (BCG), levamisole, interleukin-2, alpha-interferon, etc.
• monoclonal antibodies e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies
• immunotoxins e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.
• radioimmunotherapy e.g., anti- CD20 monoclonal antibody conjugated to U 1 ln, 90 Y, or 131 I, etc.
• triptolide triptolide
• homoharringtonine dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5- nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)-targeted therapy or therapeutic (e.g.
• EGFR epidermal growth factor receptor
• gefitinib IressaTM
• erlotinib TarcevaTM
• cetuximab ErbituxTM
• lapatinib TykerbTM
• panitumumab VectibixTM
• vandetanib CaprelsaTM
• afatinib/BIBW2992 CI-1033/canertinib, neratinib/HKI-272, CP- 724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasat
• tomaymycin carboplatin
• CC-1065 and CC-1065 analogs including amino-CBIs, nitrogen mustards (such as chlorambucil and melphalan), dolastatin and dolastatin analogs (including auristatins: eg. monomethyl auristatin E), anthracycline antibiotics (such as doxorubicin, daunorubicin, etc.), duocarmycins and duocarmycin analogs, enediynes (such as neocarzinostatin and calicheamicins), leptomycin derivaties, maytansinoids and maytansinoid analogs (e.g.
• mertansine methotrexate
• mitomycin C taxoids
• vinca alkaloids such as vinblastine and vincristine
• epothilones e.g. epothilone B
• camptothecin e.g. camptothecin and its clinical analogs topotecan and irinotecan, or the like.
• a "bioconjugate linker” is a covalent linker moiety that results from bioconjugate chemistry as generally known in the art. See for example, Bioconjugate Techniques, Second
• bioconjugate linkers can be found in Table 2 linking an adamantyl moiety (Ring A) to a variety of biomolecules, such as an antibody or peptide (e.g. modified peptide such as peptide including folate or a folate derivative).
• a linker is formed by a conjugation or bioconjugation reaction combining a first reactant moity covalently bonded to an agent (e.g., including R 1 , a protein moiety, antibody moiety, siderophore moiety, detectable moiety, or drug moiety) and a second reactant moiety covalently bonded to a linker of a compound described herein (e.g., compound of formula I, la, lb), for example a linker selected from L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , L 12 , L 13 , and L 14 .
• bioconjugation reaction including compounds as described herein may be referred to as a conjugate.
• Conjugates described herein may be synthesized using bioconjugate or conjugate chemistry.
• Conjugate chemistry includes coupling two molecules together to form an adduct. Conjugation may be a covalent modification.
• Currently favored classes of conjugate chemistry reactions available with reactive known reactive groups are those which proceed under relatively mild conditions. These include, but are not limited to nucleophilic substitutions (e.g., reactions of amines and alcohols with acyl halides, active esters), electrophilic substitutions (e.g., enamine reactions) and additions to carbon-carbon and carbon-heteroatom multiple bonds (e.g. , Michael reaction, Diels-Alder addition).
• bioconjugation reaction is a click chemistry reaction
• the bioconjugation reaction is a Huisgen cyclization of azides. In embodiments, the bioconjugation reaction is a copper catalyzed Huisgen cyclization of azides. In embodiments, the
• bioconjugation reaction is a click chemistry reaction that does not require copper.
• a nucleophilic group such as, for example, an amine, a carboxylate anion, thiol anion, carbanion, or an alkoxide ion
• dienophile groups which are capable of participating in Diels-Alder reactions such as, for example, maleimido groups;
• amine or sulfhydryl groups which can be, for example, acylated, alkylated or oxidized;
• alkenes which can undergo, for example, cycloadditions, acylation, Michael addition, etc;
• the reactive functional groups can be chosen such that they do not participate in, or interfere with, the chemical stability of the conjugate described herein. Alternatively, a reactive functional group can be protected from participating in the crosslinking reaction by the presence of a protecting group.
• “Chemotherapeutic” or “chemotherapeutic agent” is used in accordance with its plain ordinary meaning and refers to a chemical composition or compound having antineoplastic properties or the ability to inhibit the growth or proliferation of cells.
• anti-infective agent or “anti-infectious agent” or “anti-infective drug” or “anti-infective” are interchangeable and are used in accordance with their plain ordinary meaning and refer to a composition (e.g. compound, drug, antagonist, inhibitor, modulator) having anti- infectious agent properties or the ability to inhibit the growth or proliferation of an infectious agent (e.g. parasite (e.g. protozoa), bacterium, virus, fungus, or microorganism) or treat a symptom of a disease caused by an infectious agent.
• an infectious agent e.g. parasite (e.g. protozoa), bacterium, virus, fungus, or microorganism
• an anti-infective agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating infection by an infectious agent or a disease associated with an infectious agent.
• an anti-infective agent is an agent with anti-infectious agent properties that has not (e.g., yet) been approved by the FDA or similar regulatory agency of a country other than the USA, for treating infection by an infectious agent or a disease associated with an infectious agent.
• anti-infective agents include, but are not limited to, anti-viral agents, anti-bacterial agents, antibiotics, anti-parasitic (e.g. anti-protozoan) agents, anti-malarial agents, and anti-fungal agents.
• anti-bacterial agent or "anti-bacterial drug” or “anti-bacterial” or
• an anti- bacterial agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating a bacterial infection.
• an anti-bacterial agent is an agent with the ability to inhibit the growth or proliferation of bacteria that has not (e.g., yet) been approved by the FDA or similar regulatory agency of a country other than the USA, for treating a bacterial infection.
• Examples of anti- bacterial agents include, but are not limited to, Penicillins (e.g., penicillins,
• antistaphylococcal penicillins aminopenicillins, antipseudomonal penicillins
• cephalosporins polymyxins, rifamycins, lipiarmycins, quinolones, sulfonamides, macrolides, lincosamides, tetracyclines, aminoglycosides, cyclic lipopeptides (e.g., daptomycin, sufactin, echinocandins, caspofungin), glycylcyclines (e.g., tigecycline), oxazolidinones (e.g., linezolid, posizolid, tedizolid, radezolid, cycloserine), lipiarmycins (e.g., fidaxomicin), mecillinams, and
• An anti-bacterial moiety is a radical of an anti-bacterial.
• an anti-bacterial agent include Amikacin, Gentamicin, Kanamycin, Neomycin, Netilmicin, Tobramycin, Paromomycin, Streptomycin, Spectinomycin, Geldanamycin, Herbimycin, Rifaximin, Loracarbef, Ertapenem, Doripenem, Imipenem/Cilastatin, Meropenem, Cefadroxil, Cefazolin, Cefalotin or Cefalothin, Cefalexin, Cefaclor, Cefamandole, Cefoxitin, Cefprozil, Cefuroxime, Cefixime , Cefdinir, Cefditoren, Cefoperazone , Cefotaxime, Cefpodoxime, Ceftazidime , Ceftibuten, Ceftizoxime, Ceftriaxone , Cefepime
• Ceftobiprole Teicoplanin, Vancomycin, Telavancin, Dalbavancin, Oritavancin, Clindamycin, Lincomycin, Daptomycin, Azithromycin, Clarithromycin, Dirithromycin, Erythromycin, Roxithromycin, Troleandomycin, Telithromycin, Spiramycin, Aztreonam, Furazolidone, Nitrofurantoin, Linezolid, Posizolid, Radezolid, Torezolid, Amoxicillin, Ampicillin, Azlocillin, Carbenicillin, Cloxacillin, Dicloxacillin, Flucloxacillin, Mezlocillin, Methicillin, Nafcillin, Oxacillin, Penicillin G, Penicillin V, Piperacillin, Penicillin G, Temocillin, Ticarcillin,
• AmoxiciUin/clavulanate Ampicillin/sulbactam, Piperacillin/tazobactam, Ticarcillin/clavulanate, Bacitracin, Colistin, Polymyxin B, Ciprofloxacin, Enoxacin, Gatifloxacin, Gemifloxacin, Levofloxacin, Lomefloxacin, Moxifloxacin, Nalidixic acid, Norfloxacin, Ofloxacin,
• Trovafloxacin Grepafloxacin, Sparfloxacin, Temafloxacin, Mafenide, Sulfacetamide,
• Sulfadiazine Silver sulfadiazine, Sulfadimethoxine, Sulfamethizole, Sulfamethoxazole, Sulfanilimide , Sulfasalazine, Sulfisoxazole, Trimethoprim- Sulfamethoxazole (Co-trimoxazole) (TMP-SMX), Sulfonamidochrysoidine, Demeclocycline, Doxycycline, Minocycline,
• anti-malarial agent or "anti-malarial drug” or “anti-malarial” are interchangeable and are used in accordance with their plain ordinary meaning and refer to a composition (e.g. compound, drug, antagonist, inhibitor, modulator) having anti-malarial properties or the ability to inhibit the growth or proliferation of Plasmodium that infect humans (e.g. P. vivax, P.
• an anti-malarial agent treats infection with P. vivax, P. ovale, P. malariae, and/or P. falciparum.
• an anti-malarial agent treats infection with P. vivax.
• an anti-malarial agent treats infection with P. ovale.
• an anti- malarial agent treats infection with P. malariae.
• an anti-malarial agent treats infection with P. falciparum.
• an anti-malarial agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating malaria.
• an anti-malarial agent is an agent with the ability to inhibit the growth or proliferation of Plasmodium that infect humans that has not (e.g., yet) been approved by the FDA or similar regulatory agency of a country other than the USA, for treating malaria.
• anti-malarial agents include, but are not limited to, amodiaquine, atovaquone, chloroquine, clardribine, clindamycin, cytarabine, daunorubicin, docetaxel, doxorubicin, doxycycline, etoposide, fansidar, fludarabine, halofantrine, idarubicin, imiquimod, irinotecan, mefloquine, methotrexate, mitomycin, oxamniquine, paclitaxel, plicamycin, primaquine, proquanil, pyrimethamine, quinidine, quinine, topotecan, vinblastine, vincristine, KA609, KAF156, tafenoquine, and pyronaridine.
• An anti-malarial moiety is a radical of an anti-malarial.
• Patient or “subject in need thereof or “subject” refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a compound or pharmaceutical composition or by a method, as provided herein.
• Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals.
• a patient is human.
• a subject is human.
• Disease or “condition” refer to a state of being or health status of a patient or subject capable of being treated with a compound, pharmaceutical composition, or method provided herein.
• the disease is a disease having the symptom of an increased amount of Fe 11 relative to normal Fe 11 amounts in a subject (e.g. human).
• the disease is a disease having the symptom of an increased amount of a reductant (e.g.
• the disease is an infectious disease.
• the disease is a bacterial disease.
• the disease is a parasitic disease.
• the disease is a viral disease.
• the disease is malaria.
• the diease is drug-resistant malaria.
• the disease is a cancer.
• cancer refers to human cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, etc., including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, pancreas, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, and liver cancer, including hepatocarcinoma, lymphoma, including B-acute lymphoblastic lymphoma, non-Hodgkin's lymphomas (e.g., Burkitt's, Small Cell, and Large Cell lymphomas), Hodgkin's lymphoma, leukemia (including AML, ALL, and CML), or multiple myeloma.
• cancers and carcinomas, sarcomas, adenocarcinomas, lymphomas, leukemias, etc. including solid and lymphoid cancers, kidney, breast, lung, bladder, colon,
• the disease is a disease related to (e.g. caused by) an infectious agent (e.g. bacteria)
• infectious agents e.g. bacteria
• diseases, disorders, or conditions include, but are not limited to, infectious diseases, bacterial infectious diseases, nosocomial infections, nosocomial bacterial infections, ventilator associated pneumonias, bacterial blood stream infections, Cutaneous anthrax, Pulmonary anthrax, Gastrointestinal anthrax, Whooping cough, bacterial pneumonia, Lyme disease, Brucellosis, Acute enteritis, Community-acquired respiratory infection, Nongonococcal urethritis (NGU), Lymphogranuloma venereum (LGV), Trachoma, Inclusion conjunctivitis of the newborn (ICN), Psittacosis, Botulism,
• Pseudomembranous colitis Gas gangrene, Acute food poisoning, Anaerobic cellulitis, Tetanus, Diphtheria, Nosocomial infections, Urinary tract infections (UTI), Diarrhea, Meningitis in infants, Traveller's diarrhea, Diarrhea in infants, Hemorrhagic colitis, Hemolytic -uremic syndrome, Tularemia, Bacterial meningitis, Upper respiratory tract infections, Pneumonia, bronchitis, Peptic ulcer, gastric carcinoma, gastric B-cell lymphoma, Legionnaire's Disease, Pontiac fever, Leptospirosis, Listeriosis, Leprosy (Hansen's disease), Tuberculosis, Mycoplasma pneumonia, Gonorrhea, Ophthalmia neonatorum, Septic arthritis, Meningococcal disease, Waterhouse-Friderichsen syndrome, Pseudomonas infection, Bac
• Acinetobacter baumannii infection skin diseases or conditions, acne, acne vulgaris, keratosis pilaris, acne rosacea, harlequin ichthyosis, xeroderma pigmentosum, keratoses, eczema, rosacea, necrotizing fasciitis, tuberculosis, hospital-acquired pneumonia, gastroenteritis, or bacteremia.
• infectious disease refers to a disease or condition related to the presence of an organism (the agent or infectious agent) within or contacting the subject or patient. Examples include a bacterium, fungus, virus, or other microorganism.
• a "bacterial infectious disease” or “bacterial disease” is an infectious disease wherein the organism is a bacterium.
• a “viral infectious disease” or “viral disease” is an infectious disease wherein the oreanism is a virus.
• An “antibiotic resistant bacterial infectious disease” or “antibiotic resistant bacterial disease” is an infectious disease wherein the organism is a bacterium resistant to one or more antibiotics effective in treating a disease caused by the non-antibiotic resistant strains of the bacterium.
• a "penicillin resistant bacterial infectious disease” or "penicillin resistant bacterial disease” is an antibiotic resistant bacterial infectious disease wherein the disease is not treated as effectively by a penicillin or penicillin-related compounds as a similar disease caused by a bacterial strain that is not penicillin resistant.
• a "cephalosporin resistant bacterial infectious disease” or “cephalosporin resistant bacterial disease” is an antibiotic resistant bacterial infectious disease wherein the disease is not treated as effectively by a cephalosporin or cephalosporin-related compounds as a similar disease caused by a bacterial strain that is not cephalosporin resistant.
• a "beta-lactam antibiotic resistant bacterial infectious disease” or “beta- lactam antibiotic resistant bacterial disease” is a an antibiotic resistant bacterial infectious disease wherein the disease is not treated as effectively by beta-lactam containing antibiotics as a similar disease caused by a bacterial strain that is not beta-lactam antibiotic resistant.
• infectious diseases examples include nosocomial infections, bacteremia, Cutaneous anthrax , Pulmonary anthrax , Gastrointestinal anthrax , Whooping cough , bacterial pneumonia, bacteremia, Lyme disease , Brucellosis , Acute enteritis , Community-acquired respiratory infection, Nongonococcal urethritis (NGU) , Lymphogranuloma venereum (LGV) , Trachoma , Inclusion conjunctivitis of the newborn (ICN) , Psittacosis, Botulism , Pseudomembranous colitis ,Gas gangrene , Acute food poisoning , Anaerobic cellulitis , Tetanus , Diphtheria , Nosocomial infections , Urinary tract infections
• Rheumatic fever erysipelas , Puerperal fever , Necrotizing fasciitis , Syphilis , Congenital syphilis , Cholera, Plague, Bubonic plague , Pneumonic plague, Iraq war infection caused by Acinetobacter baumannii (i.e. Iraq war-related Acinetobacter baumannii infection), necrotizing fasciitis, tuberculosis, hospital-acquired pneumonia, gastroenteritis, or sepsis.
• infectious agent refers to an organism that is associated with (in or contacting) patients with an infectious disease but not in patients without the infectious disease and wherein contacting a patient without the infectious disease with the organism results in the patient having the infectious disease.
• infectious agent associated with a disease that may be treated by the compounds and/or methods described herein is a bacterium.
• the bacteria is of a genera selected from Stenotrophomonas, Clostridium, Acinetobacter, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus,
• Helicobacter Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Vibrio, Klebsiella, Enterobacter, Citrobacter, or Yersinia.
• the bacteria is selected from Stenotrophomonas maltophilia, Clostridium difficile, Bacillus anthracis, Bordetella pertussis, Borrelia burgdorferi, Brucella abortus , Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydophila psittaci, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Enterotoxigenic Escherichia coli (ETEC), Enteropathogenic E.
• Stenotrophomonas maltophilia Clostridium difficile
• Bacillus anthracis Bord
• coli E. coli 0157:H7, Francisella tularensis, Haemophilus influenzae, Helicobacter pylori, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis,
• the bacteria is gram negative. In some embodiments, the bacteria is gram positive.
• cancer refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g. humans), including leukemia, carcinomas and sarcomas.
• Exemplary cancers that may be treated with a compound or method provided herein include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, Medulloblastoma, colorectal cancer, pancreatic cancer.
• Additional examples may include, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.
• leukemia refers broadly to progressive, malignant diseases of the blood- forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non- increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic).
• Exemplary leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia,
• hemocytoblastic leukemia histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocyte leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia,
• sarcoma generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance.
• Sarcomas that may be treated with a compound or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemo
• melanoma is taken to mean a tumor arising from the melanocytic system of the skin and other organs.
• Melanomas that may be treated with a compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.
• carcinoma refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases.
• exemplary carcinomas that may be treated with a compound or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid
• signaling pathway refers to a series of interactions between cellular and optionally extra-cellular components (e.g. proteins, nucleic acids, small molecules, ions, lipids) that conveys a change in one component to one or more other components, which in turn may convey a change to additional components, which is optionally propagated to other signaling pathway components.
• extra-cellular components e.g. proteins, nucleic acids, small molecules, ions, lipids
• “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient.
• Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like.
• Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
• auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
• auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
• auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents
• preparation is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
• a carrier which is thus in association with it.
• cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
• administering means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, intranasal or subcutaneous administration, or the implantation of a slow- release device, e.g., a mini-osmotic pump, to a subject.
• Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal).
• Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
• Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc.
• co-administer it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies (e.g. anti-cancer agent, anti-infective, anti-bacterial, anti-parasitic, antimalarial).
• additional therapies e.g. anti-cancer agent, anti-infective, anti-bacterial, anti-parasitic, antimalarial.
• the compound of the invention can be administered alone or can be coadministered to the patient.
• Coadministration is meant to include simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent).
• the preparations can also be combined, when desired, with other active substances (e.g. to reduce metabolic degradation, to increase degradation of a prodrug and release of the drug, detectable agent, protein).
• the compositions of the present invention can be delivered by trans dermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
• Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient.
• Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
• Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
• the compositions of the present invention may additionally include components to provide sustained release and/or comfort. Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841;
• compositions of the present invention can also be delivered as microspheres for slow release in the body.
• microspheres can be administered via intradermal injection of drug-containing microspheres, which slowly release subcutaneouslv isee Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12:857-863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49:669-674, 1997).
• the formulations of the compositions of the present invention can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i.e., by employing receptor ligands attached to the liposome, that bind to surface membrane protein receptors of the cell resulting in endocytosis.
• liposomes particularly where the liposome surface carries receptor ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present invention into the target cells in vivo.
• the compositions of the present invention can also be delivered as nanoparticles.
• compositions provided by the present invention include compositions wherein the active ingredient (e.g. compounds described herein, including embodiments or examples) is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose.
• the actual amount effective for a particular application will depend, inter alia, on the condition being treated.
• such compositions When administered in methods to treat a disease, such compositions will contain an amount of active ingredient effective to achieve the desired result, e.g., reducing, eliminating, or slowing the progression of disease symptoms (e.g. symptoms of cancer, an infectious disease, or malaria). Determination of a therapeutically effective amount of a compound of the invention is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure herein.
• the dosage and frequency (single or multiple doses) administered to a mammal can vary depending upon a variety of factors, for example, whether the mammal suffers from another disease, and its route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated (e.g. symptoms of cancer, an infectious disease, or malaria), kind of concurrent treatment, complications from the disease being treated or other health-related problems.
• Other therapeutic regimens or agents can be used in conjunction with the methods and compounds of Applicants' invention.
• Adjustment and manipulation of established dosages are well within the ability of those skilled in the art.
• the therapeutically effective amount can be initially determined from cell culture assays.
• Target concentrations will be those concentrations of active compound(s) that are capable of achieving the methods described herein, as measured using the methods described herein or known in the art.
• therapeutically effective amounts for use in humans can also be determined from animal models.
• a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals.
• the dosage in humans can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above. Adjusting the dose to achieve maximal efficacy in humans based on the methods described above and other methods is well within the capabilities of the ordinarily skilled artisan.
• Dosages may be varied depending upon the requirements of the patient and the compound being employed. The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time.
• the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
• Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
• an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is effective to treat the clinical symptoms demonstrated by the particular patient.
• This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration and the toxicity profile of the selected agent.
• the compounds described herein can be used in combination with one another, with other active agents known to be useful in treating cancer, or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
• co-administration includes administering one active agent within 0.5, 1 , 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent.
• Co-administration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order.
• co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents.
• the active agents can be formulated separately.
• the active and/or adjunctive agents may be linked or conjugated to one another.
• the compounds described herein may be combined with treatments for cancer such as radiation or surgery.
• L 11 , and L 12 are independently a bond, -
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 is, for example a biomolecule such as a protein moiety (e.g antibody moiety, peptide moiety, modified peptide moiety such as peptide moiety including folate).
• L 10 is - N(-L n -R u )- or -C((-L n -R n )(-L 12 -R 12 ))-.
• Each L 13 and L 14 are independently selected from a bond, -
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 is, for example a biomolecule such as a protein moiety (e.g antibody, peptide, modified peptide such as peptide including folate).
• a biomolecule such as a protein moiety (e.g antibody, peptide, modified peptide such as peptide including folate).
• the symbols m and v are independently 1 or 2.
• n is independently an integer from 0 to 2.
• Y is - 0-, -S-, -00-, -CH 2 0-, or -OCH 2 -.
• X is independently -CI, -Br, -I, or -F.
• the compounds described herein are prodrugs, wherein the prodrug moiety is the component of the compound that is not a drug moiety/detectable moiety/protein moiety and is released from the drug moiety/detectable moiety/protein moiety upon degradation of the prodrug in the presence of a high level of reductant (e.g. biological reductant, Fe 11 ).
• a high level of reductant e.g. biological reductant, Fe 11
• degradation of the prodrug in the presence of a high level of reductant e.g.
• biological reductant, Fe 11 includes opening of the peroxide containing ring (e.g. trioxolane) in the prodrug moiety and release of an active drug/detectable agent/protein (e.g. where the monovalent moiety is cleaved to form a compound with full valency).
• an active drug/detectable agent/protein e.g. where the monovalent moiety is cleaved to form a compound with full valency.
• the drug/detectable agent/protein and drug moiety/detectable moiety/protein moiety include only those compounds compatible with the chemistry provided herein for connecting the drug moiety/detectable moiety/protein moiety to the prodrug moiety and for release of the drug/detectable agent/protein from the compound (prodrug) by the presence of a high level of reductant (e.g. biological reductant, Fe 11 ).
• degradation of the prodrug to release an active agent may result in an active agent including a linker or portion of the peroxide containing ring in the active agent.
• an active agent e.g., drug, protein, detectable agent, active compound
• the resulting active agent includes a higher level of activity compared to the level of activity of the intact prodrug.
• a drug moiety is i) a radical composition that upon release (cleavage of the bond connecting the drug moiety to the prodrug moiety) from a compound (i.e. prodrugs) described herein, forms a drug (e.g. therapeutic agent); and ii) is connected to the prodrug moiety by a bond to an N atom of the drug moiety.
• a drug moiety is i) a radical composition that upon release (cleavage of the bond connecting the drug moiety to the prodrug moiety) from a compound (i.e. prodrugs) described herein, forms a drug (e.g.
• a drug moiety is i) a radical composition that upon release (cleavage of the bond connecting the drug moiety to the prodrug moiety) from a compound (i.e. prodrugs) described herein, forms a drug (e.g. therapeutic agent); and ii) is connected to the prodrug moiety by a bond to an S atom of the drug moiety.
• a drug moiety is i) a radical composition that unon release (cleavage of the bond connecting the drug moiety to the prodrug moiety) from a compound (i.e.
• the drug moiety is an anti-cancer agent moiety (e.g., described herein).
• the drug moiety is an anti-infective agent moiety (e.g., described herein).
• the drug moiety is an anti-malaria agent moiety (e.g., described herein).
• the drug moiety is an anti-bacterial agent moiety (e.g., described herein).
• the drug moiety is an antibiotic moiety (e.g., described herein).
• the drug moiety is an anti-parasitic agent moiety (e.g., described herein).
• a detectable moiety is i) a radical composition that upon release (cleavage of the bond connecting the detectable moiety to the prodrug moiety) from a compound (i.e. prodrugs) described herein, forms a detectable agent (e.g. fluorescent agent); and ii) is connected to the prodrug moiety by a bond to an N atom of the detectable moiety.
• a detectable moiety is i) a radical composition that upon release (cleavage of the bond connecting the detectable moiety to the prodrug moiety) from a compound (i.e. prodrugs) described herein, forms a detectable agent (e.g.
• a detectable moiety is i) a radical composition that upon release (cleavage of the bond connecting the detectable moiety to the prodrug moiety) from a compound (i.e. prodrugs) described herein, forms a detectable agent (e.g. fluorescent agent); and ii) is connected to the prodrug moiety by a bond to an S atom of the detectable moiety.
• a drug moiety is i) a radical composition that upon release (cleavage of the bond connecting the drug moiety to the prodrug moiety) from a compound (i.e.
• a protein moiety is i) a radical composition that upon release (cleavage of the bond connecting the protein moiety to the prodrug moiety) from a compound (i.e.
• a protein moiety is i) a radical composition that upon release (cleavage of the bond connecting the protein moiety to the prodrug moiety) from a compound (i.e. prodrugs) described herein, forms a protein (e.g antibody); and ii) is connected to the prodrug moiety by a bond to an O atom of the protein moiety.
• a protein moiety is i) a radical composition that upon release (cleavage of the bond connecting the protein moiety to the prodrug moiety) from a compound (i.e.
• a drug moiety is i) a radical composition that upon release (cleavage of the bond connecting the drug moiety to the prodrug moiety) from a compound (i.e. prodrugs) described herein, forms a drug (e.g. therapeutic agent); and ii) is connected to the prodrug moiety by a bond to a -OC(0)-(remainder of protein moiety) of the protein moiety.
• Y is -0-. In embodiments, Y is -S-. In embodiments, Y is -00-. In embodiments, Y is -CH 2 0-. In embodiments, Y is -OCH 2 -. In embodiments, R 17 is
• L 10 is -N(-L u -R n )- In embodiments, L 10 is -CCC-L ⁇ -R ⁇ X-L ⁇ -R"))-.
• m is independently 1. In embodiments, m is independently 2.
• v is independently 1. In embodiments, v is independently 2.
• n is independently 0. In embodiments, n is independently 1. In embodiments, n is independently 2.
• X is independently -CI. In embodiments, X is independently -Br. In embodiments, X is independently -I. In embodiments, X is
• R 2 and R 3 , R 4 and R 5 , R 6 and R 7 , R 8 and R 9 , or R 11 and R 12 may be joined to form a substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl.
• R 4 is a protein moiety. In embodiments, R 4 is a drug moiety. In embodiments, R 4 is a detectable moiety. In embodiments, R 5 is a protein moiety.
• R 5 is a drug moiety. In embodiments, R 5 is a detectable moiety. In embodiments, R 6 is a protein moiety. In embodiments, R 6 is a drug moiety. In embodiments, R 6 is a detectable moiety. In embodiments, R 7 is a protein moiety. In embodiments, R 7 is a drug moiety. In embodiments, R 7 is a detectable moiety. In embodiments, R 11 is a protein moiety. In embodiments, R 11 is a drug moiety. In embodiments, R 11 is a detectable moiety. In
• R 12 is a protein moiety. In embodiments, R 12 is a drug moiety. In embodiments, R 12 is a detectable moiety. In embodiments, R 2 is a protein moiety. In embodiments, R 2 is a drug moiety. In embodiments, R 2 is a detectable moiety. In embodiments, R 3 is a protein moiety. In embodiments, R 3 is a drug moiety. In embodiments, R 3 is a detectable moiety. In embodiments, R 8 is a protein moiety. In embodiments, R 8 is a drug moiety. In embodiments, R 8 is a detectable moiety. In embodiments, R 9 is a protein moiety. In embodiments, R 9 is a drug moiety. In embodiments, R 9 is a drug moiety.
• R 9 is a detectable moiety.
• R 2 is an antibody moiety.
• R 3 is an antibody moiety.
• R 4 is an antibody moiety.
• R 5 is an antibody moiety.
• R 6 is an antibody moiety.
• R 7 is an antibody moiety.
• R 8 is an antibody moiety.
• R 9 is an antibody moiety.
• R 11 is an antibody moiety.
• R 12 is an antibody moiety.
• R 2 is a siderophore moiety.
• R 3 is a siderophore moiety.
• R 4 is a siderophore moiety.
• R 5 is a siderophore moiety.
• R 6 is a siderophore moiety.
• R 7 is a siderophore moiety.
• R 8 is a siderophore moiety.
• R 9 is a siderophore moiety.
• R 11 is a siderophore moiety.
• R 12 is a siderophore moiety.
• a compound described herein (prodrug described herein) including a drug moiety is less active than the corresponding free drug.
• a compound described herein does not have the activity of the free drug.
• a compound described herein has less than 0.9 times the activity of the free drug (e.g. less than 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, or 0.001 times the activity of the free drug).
• Drug moieties that form part of the prodrugs described herein may obtain functionality due to chemical changes in the prodrugs that occur under physiological conditions.
• a compound described herein (prodrug described herein) including a detectable moiety is less detectable than the corresponding free detectable agent.
• a prodrug compound including a detectable moiety described herein cannot be detected using an identical method capable of detecting the free detectable agent.
• a prodrug compound including a detectable moiety described herein is less than 0.9 times as detectable as the free detectable moiety (e.g. less than 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, or 0.001 times as detectable as the free detectable moiety using the same method (e.g. assay)).
• a prodrug compound including a detectable moiety described herein is at least 0.9 times as detectable as the free detectable moiety (e.g.
• a compound described herein can be detected with the same sensitivity as the free detectable agent using an identical method of detection.
• a compound described herein includes one drug moiety.
• a compound described herein includes a plurality of optionally different drug moieties. In embodiments, a compound described herein includes one detectable moiety. In embodiments, a compound described herein includes a plurality of optionally different detectable moieties. In embodiments, a compound described herein includes one protein moiety. In embodiments, a compound described herein includes a plurality of optionally different protein moieties. In embodiments, a compound described herein includes at least one drug moiety and at least one detectable moiety. In embodiments, a compound described herein includes at least one drug moiety and at least one protein moiety. In embodiments, a compound described herein includes at least one protein moiety and at least one detectable moiety.
• a compound described herein includes at least one protein moiety, at least one drug moiety, and at least one detectable moiety. In embodiments, a compound described herein includes one antibody moiety. In embodiments, a compound described herein includes a plurality of optionally different antibody moieties. In embodiments, a compound described herein includes one siderophore moiety. In embodiments, a compound described herein includes a plurality of optionally different siderophore moieties.
• L 2 is a bond. In embodiments L 2 is -OC(O)-. In embodiments L 2 is -OC(0)NH-Ph-CH 2 -. In embodiments L 2 is -OC(0)NH-Ph-CH 2 -OC(0)-. In embodiments L 2 is -NH-Ph-CH 2 -. In embodiments L 2 is -NH-Ph-CH 2 -OC(0)-. In embodiments L 2 is -O-Ph- CH 2 -. In embodiments L 2 is -0-Ph-CH 2 -OC(0)-. In embodiment, R 2 is a protein moiety. In embodiment, R 2 is a protein moiety bonded to L 2 through an N of the protein moiety.
• R 2 is a protein moiety bonded to L 2 through an O of the protein moiety. In embodiment, R 2 is a protein moiety bonded to L 2 through an S of the protein moiety. In embodiment, R 2 is a protein moiety bonded to L 2 through an O of a -OC(O)- of the protein moiety. In embodiment, R 2 is a detectable moiety. In embodiment, R 2 is a detectable moiety bonded to L 2 through an N of the detectable moiety. In embodiment, R 2 is a detectable moiety bonded to L 2 through an O of the detectable moiety. In embodiment, R 2 is a detectable moiety bonded to L 2 through an S of the detectable moiety.
• R 2 is a detectable moiety bonded to L 2 through an O of a -OC(O)- of the detectable moiety.
• R 2 is a drug moiety.
• R 2 is a drug moiety bonded to L 2 through an N of the drug moiety.
• R 2 is a drug moiety bonded to L 2 through an O of the drug moiety.
• R 2 is a drug moiety bonded to L 2 through an S of the drug moiety.
• R 2 is a drug moiety bonded to L 2 through an O of a -OC(O)- of the drug moiety.
• L 3 is a bond. In embodiments L 3 is -OC(O)-. In embodiments L 3 is -OC(0)NH-Ph-CH 2 -. In embodiments L 3 is -OC(0)NH-Ph-CH 2 -OC(0)-. In embodiments
• L 3 is -NH-Ph-CH 2 -. In embodiments L 3 is -NH-Ph-CH 2 -OC(0)-. In embodiments L 3 is -O-Ph- CH2-. In embodiments L 3 is -0-Ph-CH 2 -OC(0)-. In embodiment, R 3 is a protein moiety. In embodiment, R 3 is a protein moiety bonded to L 3 through an N of the protein moiety. In embodiment, R 3 is a protein moiety bonded to L 3 through an O of the protein moiety. In embodiment, R 3 is a protein moiety bonded to L 3 through an S of the protein moiety.
• R 3 is a protein moiety bonded to L 3 through an O of a -OC(O)- of the protein moiety. In embodiment, R 3 is a detectable moiety. In embodiment, R 3 is a detectable moiety bonded to L 3 through an N of the detectable moiety. In embodiment, R 3 is a detectable moiety bonded to L 3 through an O of the detectable moiety. In embodiment, R 3 is a detectable moiety bonded to L 3 through an S of the detectable moiety. In embodiment, R 3 is a detectable moiety bonded to L 3 through an O of a -OC(O)- of the detectable moiety. In embodiment, R 3 is a drug moiety.
• R 3 is a drug moiety bonded to L 3 through an N of the drug moiety. In embodiment, R 3 is a drug moiety bonded to L 3 through an O of the drug moiety. In embodiment, R 3 is a drug moiety bonded to L 3 through an S of the drug moiety. In embodiment, R 3 is a drug moiety bonded to L 3 through an O of a -OC(O)- of the drug moiety. In embodiments, L 3 is a substituted or unsubstituted C1-C2 0 alkylene. In embodiments, L 3 is a substituted or
• L 3 is a substituted or unsubstituted 2 to 20 membered heteroalkylene.
• L 3 is a substituted or unsubstituted C3-C2 0 cycloalkylene.
• L 3 is a substituted or unsubstituted 3 to 20 membered heterocycloalkylene.
• L 3 is a substituted or unsubstituted C6-C2 0 arylene.
• L 3 is a substituted or unsubstituted 5 to 20 membered heteroarylene.
• L 3 is a substituted C1-C2 0 alkylene.
• L 3 is a substituted 2 to 20 membered heteroalkylene.
• L 3 is a substituted C3-C20 cycloalkylene. In embodiments, L 3 is a substituted 3 to 20 membered heterocycloalkylene. In embodiments, L 3 is a substituted C6-C2 0 arylene. In embodiments, L 3 is a substituted 5 to 20 membered
• L 3 is an unsubstituted C1-C2 0 alkylene. In embodiments, L 3 is an unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 3 is an unsubstituted C3- C2 0 cycloalkylene. In embodiments, L 3 is an unsubstituted 3 to 20 membered
• L 3 is an unsubstituted C6-C2 0 arylene. In embodiments, L 3 is an unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 3 is a substituted or unsubstituted C1-C14 alkylene. In embodiments, L 3 is a substituted or unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 3 is a substituted or unsubstituted C3-C 4 cycloalkylene. In embodiments, L 3 is a substituted or unsubstituted 3 to 14 membered heterocycloalkylene.
• L 3 is a substituted or unsubstituted C6-C14 arylene. In embodiments, L 3 is a substituted or unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 3 is a substituted C1-C14 alkylene. In embodiments, L 3 is a substituted 2 to 14 membered heteroalkylene. In embodiments, L 3 is a substituted C3-C14 cycloalkylene. In embodiments, L 3 is a substituted 3 to 14 membered heterocycloalkylene. In embodiments, L 3 is a substituted C6-C14 arylene. In embodiments, L 3 is a substituted 5 to 14 membered
• L 3 is an unsubstituted C1-C 4 alkylene. In embodiments, L 3 is an unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 3 is an unsubstituted C3- Ci4 cycloalkylene. In embodiments, L 3 is an unsubstituted 3 to 14 membered
• L 3 is an unsubstituted C6-C14 arylene. In embodiments, L 3 is an unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 3 is a substituted or unsubstituted Ci-Cs alkylene. In embodiments, L 3 is a substituted or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 3 is a substituted or unsubstituted C3-C8 cycloalkylene. In embodiments, L 3 is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene.
• L 3 is a substituted or unsubstituted C6-C1 0 arylene. In embodiments, L 3 is a substituted or unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 3 is a substituted Ci-Cs alkylene. In embodiments, L 3 is a substituted 2 to 8 membered heteroalkylene. In embodiments, L 3 is a substituted C3-C8 cycloalkylene. In embodiments, L 3 is a substituted 3 to 8 membered heterocycloalkylene. In embodiments, L 3 is a substituted C6-C1 0 arylene. In embodiments, L 3 is a substituted 5 to 10 membered heteroarylene.
• L 3 is an unsubstituted Ci-Cs alkylene. In embodiments, L 3 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 3 is an unsubstituted C3-C8 cycloalkylene. In embodiments, L 3 is an unsubstituted 3 to 8 membered heterocycloalkylene. In embodiments, L 3 is an unsubstituted C6-C10 arylene. In embodiments, L 3 is an unsubstituted 5 to 10 membered heteroarylene.
• L 4 is a bond. In embodiments L 4 is -OC(O)-. In embodiments L 4 is -OC(0)NH-Ph-CH 2 -. In embodiments L 4 is -OC(0)NH-Ph-CH 2 -OC(0)-. In embodiments L 4 is -NH-Ph-CH 2 -. In embodiments L 4 is -NH-Ph-CH 2 -OC(0)-. In embodiments L 4 is -O-Ph- CH 2 -. In embodiments L 4 is -0-Ph-CH 2 -OC(0)-. In embodiment, R 4 is a protein moiety. In embodiment, R 4 is a protein moiety bonded to L 4 through an N of the protein moiety.
• R 4 is a protein moiety bonded to L 4 through an O of the protein moiety. In embodiment, R 4 is a protein moiety bonded to L 4 through an S of the protein moiety. In embodiment, R 4 is a protein moiety bonded to L 4 through an O of a -OC(O)- of the protein moiety. In embodiment, R 4 is a detectable moiety. In embodiment, R 4 is a detectable moiety bonded to L 4 through an N of the detectable moiety. In embodiment, R 4 is a detectable moiety bonded to L 4 through an O of the detectable moiety. In embodiment, R 4 is a detectable moiety bonded to L 4 through an S of the detectable moiety.
• R 4 is a detectable moiety bonded to L 4 through an O of a -OC(O)- of the detectable moiety.
• R 4 is a drug moiety.
• R 4 is a drug moiety bonded to L 4 through an N of the drug moiety.
• R 4 is a drug moiety bonded to L 4 through an O of the drug moiety.
• R 4 is a drug moiety bonded to L 4 through an S of the drug moiety.
• R 4 is a drug moiety bonded to L 4 through an O of a -OC(O)- of the drug moiety.
• L 5 is a bond. In embodiments L 5 is -OC(O)-. In embodiments L 5 is -OC(0)NH-Ph-CH 2 -. In embodiments L 5 is -OC(0)NH-Ph-CH 2 -OC(0)-. In embodiments L 5 is -NH-Ph-CH 2 -. In embodiments L 5 is -NH-Ph-CH 2 -OC(0)-. In embodiments L 5 is -O-Ph- CH 2 -. In embodiments L 5 is -0-Ph-CH 2 -OC(0)-. In embodiment, R 5 is a protein moiety. In embodiment, R 5 is a protein moiety bonded to L 5 through an N of the protein moiety.
• R 5 is a protein moiety bonded to L 5 through an O of the protein moiety. In embodiment, R 5 is a protein moiety bonded to L 5 through an S of the protein moiety. In embodiment, R 5 is a protein moiety bonded to L 5 through an O of a -OC(O)- of the protein moiety. In embodiment, R 5 is a detectable moiety. In embodiment, R 5 is a detectable moiety bonded to L 5 through an N of the detectable moiety. In embodiment, R 5 is a detectable moiety bonded to L 5 through an O of the detectable moiety. In embodiment, R 5 is a detectable moiety bonded to L 5 through an S of the detectable moiety.
• R 5 is a detectable moiety bonded to L 5 through an O of a -OC(O)- of the detectable moiety.
• R 5 is a drug moiety.
• R 5 is a drug moiety bonded to L 5 through an N of the drug moiety.
• R 5 is a drug moiety bonded to L 5 through an O of the drug moiety.
• R 5 is a drug moiety bonded to L 5 through an S of the drug moiety.
• R 5 is a drug
• L 5 is a substituted or unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 5 is a substituted or unsubstituted C 3 -C2 0 cycloalkylene. In embodiments, L 5 is a substituted or unsubstituted 3 to 20 membered heterocycloalkylene. In embodiments, L 5 is a substituted or unsubstituted C6-C20 arylene. In embodiments, L 5 is a substituted or unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 5 is a substituted C1-C2 0 alkylene.
• L 5 is a substituted 2 to 20 membered heteroalkylene. In embodiments, L 5 is a substituted C 3 -C2 0 cycloalkylene. In embodiments, L 5 is a substituted 3 to 20 membered heterocycloalkylene. In embodiments, L 5 is a substituted C6-C2 0 arylene. In embodiments, L 5 is a substituted 5 to 20 membered heteroarylene. In embodiments, L 5 is an unsubstituted C1-C2 0 alkylene. In embodiments, L 5 is an unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 5 is an unsubstituted C3- C2 0 cycloalkylene. In embodiments, L 5 is an unsubstituted 3 to 20 membered
• L 5 is an unsubstituted C6-C2 0 arylene. In embodiments, L 5 is an unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 5 is a substituted or unsubstituted C1-C14 alkylene. In embodiments, L 5 is a substituted or unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 5 is a substituted or unsubstituted C 3 -C 4 cycloalkylene. In embodiments, L 5 is a substituted or unsubstituted 3 to 14 membered heterocycloalkylene.
• L 5 is a substituted or unsubstituted C6-C14 arylene. In embodiments, L 5 is a substituted or unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 5 is a substituted C1-C14 alkylene. In embodiments, L 5 is a substituted 2 to 14 membered heteroalkylene. In embodiments, L 5 is a substituted C 3 -C14 cycloalkylene. In embodiments, L 5 is a substituted 3 to 14 membered heterocycloalkylene. In embodiments, L 5 is a substituted C6-C14 arylene. In embodiments, L 5 is a substituted 5 to 14 membered heteroarylene.
• L 5 is an unsubstituted C1-C 4 alkylene. In embodiments, L 5 is an unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 5 is an unsubstituted C3- Ci4 cycloalkylene. In embodiments, L 5 is an unsubstituted 3 to 14 membered heterocycloalkylene. In embodiments, L 5 is an unsubstituted C6-C14 arylene. In embodiments, L 5 is an unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 5 is a substituted or unsubstituted Ci-Cs alkylene.
• L 5 is a substituted or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 5 is a substituted or unsubstituted C3-C8 cycloalkylene. In embodiments, L 5 is a substituted or unsubstituted 3 to 8 membered
• L 5 is a substituted or unsubstituted C6-C10 arylene. In embodiments, L 5 is a substituted or unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 5 is a substituted Ci-Cs alkylene. In embodiments, L 5 is a substituted 2 to 8 membered heteroalkylene. In embodiments, L 5 is a substituted C3-C8 cycloalkylene. In embodiments, L 5 is a substituted 3 to 8 membered heterocycloalkylene. In embodiments, L 5 is a substituted C6-C1 0 arylene.
• L 5 is a substituted 5 to 10 membered heteroarylene. In embodiments, L 5 is an unsubstituted Ci-Cs alkylene. In embodiments, L 5 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 5 is an unsubstituted C3-C8 cycloalkylene. In embodiments, L 5 is an unsubstituted 3 to 8 membered heterocycloalkylene. In embodiments, L 5 is an unsubstituted C6-C1 0 arylene. In embodiments, L 5 is an unsubstituted 5 to 10 membered heteroarylene.
• L 6 is a bond. In embodiments L 6 is -OC(O)-. In embodiments L 6 is -OC(0)NH-Ph-CH 2 -. In embodiments L 6 is -OC(0)NH-Ph-CH 2 -OC(0)-. In embodiments L 6 is -NH-Ph-CH 2 -. In embodiments L 6 is -NH-Ph-CH 2 -OC(0)-. In embodiments L 6 is -O-Ph- CH 2 -. In embodiments L 6 is -0-Ph-CH 2 -OC(0)-. In embodiment, R 6 is a protein moiety. In embodiment, R 6 is a protein moiety bonded to L 6 through an N of the protein moiety.
• R 6 is a protein moiety bonded to L 6 through an O of the protein moiety. In embodiment, R 6 is a protein moiety bonded to L 6 through an S of the protein moiety. In embodiment, R 6 is a protein moiety bonded to L 6 through an O of a -OC(O)- of the protein moiety. In embodiment, R 6 is a detectable moiety. In embodiment, R 6 is a detectable moiety bonded to L 6 through an N of the detectable moiety. In embodiment, R 6 is a detectable moiety bonded to L 6 through an O of the detectable moiety. In embodiment, R 6 is a detectable moiety bonded to L 6 through an S of the detectable moiety.
• R 6 is a detectable moiety bonded to L 6 through an O of a -OC(O)- of the detectable moiety.
• R 6 is a drug moiety.
• R 6 is a drug moiety bonded to L 6 through an N of the drug moiety.
• R 6 is a drug moiety bonded to L 6 through an O of the drug moiety.
• R 6 is a drug moiety bonded to L 6 through an S of the drug moiety.
• R 6 is a drug moietv bonded to L 6 through an O of a -OC(O)- of the drug moiety.
• L 7 is a bond.
• L 7 is -OC(O)-.
• L 7 is -OC(0)NH-Ph-CH 2 -.
• L 7 is -OC(0)NH-Ph-CH 2 -OC(0)-.
• L 7 is -NH-Ph-CH 2 -.
• L 7 is -NH-Ph-CH 2 -OC(0)-.
• L 7 is -O-Ph- CH 2 -.
• L 7 is -0-Ph-CH 2 -OC(0)-.
• R 7 is a protein moiety.
• R 7 is a protein moiety bonded to L 7 through an N of the protein moiety.
• R 7 is a protein moiety bonded to L 7 through an O of the protein moiety.
• R 7 is a protein moiety bonded to L 7 through an S of the protein moiety.
• R 7 is a protein moiety bonded to L 7 through an O of a -OC(O)- of the protein moiety.
• R 7 is a detectable moiety.
• R 7 is a detectable moiety bonded to L 7 through an N of the detectable moiety.
• R 7 is a detectable moiety bonded to L 7 through an O of the detectable moiety. In embodiment, R 7 is a detectable moiety bonded to L 7 through an S of the detectable moiety. In embodiment, R 7 is a detectable moiety bonded to L 7 through an O of a -OC(O)- of the detectable moiety. In embodiment, R 7 is a drug moiety. In embodiment, R 7 is a drug moiety bonded to L 7 through an N of the drug moiety. In embodiment, R 7 is a drug moiety bonded to L 7 through an O of the drug moiety. In embodiment, R 7 is a drug moiety bonded to L 7 through an S of the drug moiety. In embodiment, R 7 is a drug
• R 7 is .
• R 7 is , X is halide (e.g., CI or Br). In embodiments, R 7 is . in embodiments, L 7 is a substituted or unsubstituted C1-C2 0 alkylene. In embodiments, L 7 is a substituted or unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 7 is a substituted or unsubstituted C3-C2 0 cycloalkylene. In embodiments, L 7 is a substituted or unsubstituted 3 to 20 membered heterocycloalkylene. In embodiments, L 7 is a substituted or unsubstituted C6-C20 arylene.
• L 7 is a substituted or unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 7 is a substituted C1-C2 0 alkylene. In embodiments, L 7 is a substituted 2 to 20 membered heteroalkylene. In embodiments, L 7 is a substituted C3-C2 0 cycloalkylene. In embodiments, L 7 is a substituted 3 to 20 membered heterocycloalkylene. In embodiments, L 7 is a substituted C6-C2 0 arylene. In embodiments, L 7 is a substituted 5 to 20 membered heteroarylene. In embodiments, L 7 is an unsubstituted C1-C2 0 alkylene.
• L 7 is an unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 7 is an unsubstituted C3- C2 0 cycloalkylene. In embodiments, L 7 is an unsubstituted 3 to 20 membered
• L 7 is an unsubstituted C6-C2 0 arylene. In embodiments, L 7 is an unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 7 is a substituted or unsubstituted C1-C14 alkylene. In embodiments, L 7 is a substituted or unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 7 is a substituted or unsubstituted C3-C 4 cycloalkylene. In embodiments, L 7 is a substituted or unsubstituted 3 to 14 membered heterocycloalkylene.
• L 7 is a substituted or unsubstituted C6-C14 arylene. In embodiments, L 7 is a substituted or unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 7 is a substituted C1-C14 alkylene. In embodiments, L 7 is a substituted 2 to 14 membered heteroalkylene. In embodiments, L 7 is a substituted C3-C14 cycloalkylene. In embodiments, L 7 is a substituted 3 to 14 membered heterocycloalkylene. In embodiments, L 7 is a substituted C6-C14 arylene. In embodiments, L 7 is a substituted 5 to 14 membered heteroarylene.
• L 7 is an unsubstituted C1-C 4 alkylene. In embodiments, L 7 is an unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 7 is an unsubstituted C3- Ci4 cycloalkylene. In embodiments, L 7 is an unsubstituted 3 to 14 membered
• L 7 is an unsubstituted C6-C14 arylene. In embodiments, L 7 is an unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 7 is a substituted or unsubstituted Ci-Cs alkylene. In embodiments, L 7 is a substituted or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 7 is a substituted or unsubstituted C3-C8 cycloalkylene. In embodiments, L 7 is a substituted or unsubstituted 3 to 8 membered
• L 7 is a substituted or unsubstituted C6-C1 0 arylene. In embodiments, L 7 is a substituted or unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 7 is a substituted Ci-Cs alkylene. In embodiments, L 7 is a substituted 2 to 8 membered heteroalkylene. In embodiments, L 7 is a substituted C3-C8 cycloalkylene. In embodiments, L 7 is a substituted 3 to 8 membered heterocycloalkylene. In embodiments, L 7 is a substituted C6-C10 arylene.
• L 7 is a substituted 5 to 10 membered heteroarylene. In embodiments, L 7 is an unsubstituted Ci-Cs alkylene. In embodiments, L 7 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 7 is an unsubstituted C3-C8 cycloalkylene. In embodiments, L 7 is an unsubstituted 3 to 8 membered heterocycloalkylene. In embodiments, L 7 is an unsubstituted C6-C1 0 arylene. In embodiments, L 7 is an unsubstituted 5 to 10 membered heteroarylene.
• L 8 is a bond. In embodiments L 8 is -OC(O)-. In embodiments L 8 is -OC(0)NH-Ph-CH 2 -. In embodiments L 8 is -OC(0)NH-Ph-CH 2 -OC(0)-. In embodiments L 8 is -NH-Ph-CH 2 -. In embodiments L 8 is -NH-Ph-CH 2 -OC(0)-. In embodiments L 8 is -O-Ph- CH 2 -. In embodiments L 8 is -0-Ph-CH 2 -OC(0)-. In embodiment, R 8 is a protein moiety. In embodiment, R 8 is a protein moiety bonded to L 8 through an N of the protein moiety.
• R 8 is a protein moiety bonded to L 8 through an O of the protein moiety. In embodiment, R 8 is a protein moiety bonded to L 8 through an S of the protein moiety. In embodiment, R 8 is a protein moiety bonded to L 8 through an O of a -OC(O)- of the protein moiety. In embodiment, R 8 is a detectable moiety. In embodiment, R 8 is a detectable moiety bonded to L 8 through an N of the detectable moiety. In embodiment, R 8 is a detectable moiety bonded to L 8 through an O of the detectable moiety. In embodiment, R 8 is a detectable moiety bonded to L 8 through an S of the detectable moiety.
• R 8 is a detectable moiety bonded to L 8 through an O of a -OC(O)- of the detectable moiety.
• R 8 is a drug moiety.
• R 8 is a drug moiety bonded to L 8 through an N of the drug moiety.
• R 8 is a drug moiety bonded to L 8 through an O of the drug moiety.
• R 8 is a drug moiety bonded to L 8 through an S of the drug moiety.
• R 8 is a drug moiety bonded to L 8 through an O of a -OC(O)- of the drug moiety.
• L 9 is a bond.
• L 9 is -OC(O)-.
• L 9 is -OC(0)NH-Ph-CH 2 -. In embodiments L 9 is -OC(0)NH-Ph-CH 2 -OC(0)-. In embodiments L 9 is -NH-Ph-CH 2 -. In embodiments L 9 is -NH-Ph-CH 2 -OC(0)-. In embodiments L 9 is -O-Ph- CH 2 -. In embodiments L 9 is -0-Ph-CH 2 -OC(0)-. In embodiment, R 9 is a protein moiety. In embodiment, R 9 is a protein moiety bonded to L 9 through an N of the protein moiety. In embodiment, R 9 is a protein moiety bonded to L 9 through an O of the protein moiety.
• R 9 is a protein moiety bonded to L 9 through an S of the protein moiety. In embodiment, R 9 is a protein moiety bonded to L 9 through an O of a -OC(O)- of the protein moiety. In embodiment, R 9 is a detectable moiety. In embodiment, R 9 is a detectable moiety bonded to L 9 through an N of the detectable moiety. In embodiment, R 9 is a detectable moiety bonded to L 9 through an O of the detectable moiety. In embodiment, R 9 is a detectable moiety bonded to L 9 through an S of the detectable moiety. In embodiment, R 9 is a detectable moiety bonded to L 9 through an O of a -OC(O)- of the detectable moiety.
• R 9 is a drug moiety. In embodiment, R 9 is a drug moiety bonded to L 9 through an N of the drug moiety. In embodiment, R 9 is a drug moiety bonded to L 9 through an O of the drug moiety. In embodiment, R 9 is a drug moiety bonded to L 9 through an S of the drug moiety. In embodiment, R 9 is a drug moiety bonded to L 9 through an O of a -OC(O)- of the drug moiety. In embodiments, L 9 is a substituted or unsubstituted C1-C20 alkylene. In embodiments, L 9 is a substituted or
• L 9 is a substituted or unsubstituted 2 to 20 membered heteroalkylene.
• L 9 is a substituted or unsubstituted C3-C2 0 cycloalkylene.
• L 9 is a substituted or unsubstituted 3 to 20 membered heterocycloalkylene.
• L 9 is a substituted or unsubstituted C6-C2 0 arylene.
• L 9 is a substituted or unsubstituted 5 to 20 membered heteroarylene.
• L 9 is a substituted C1-C2 0 alkylene.
• L 9 is a substituted 2 to 20 membered heteroalkylene.
• L 9 is a substituted C3-C2 0 cycloalkylene. In embodiments, L 9 is a substituted 3 to 20 membered heterocycloalkylene. In embodiments, L 9 is a substituted C6-C2 0 arylene. In embodiments, L 9 is a substituted 5 to 20 membered
• L 9 is an unsubstituted C1-C2 0 alkylene. In embodiments, L 9 is an unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 9 is an unsubstituted C3- C2 0 cycloalkylene. In embodiments, L 9 is an unsubstituted 3 to 20 membered
• L 9 is an unsubstituted C6-C2 0 arylene. In embodiments, L 9 is an unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 9 is a substituted or unsubstituted C1-C14 alkylene. In embodiments, L 9 is a substituted or unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 9 is a substituted or unsubstituted C3-C 4 cycloalkylene. In embodiments, L 9 is a substituted or unsubstituted 3 to 14 membered heterocycloalkylene.
• L 9 is a substituted or unsubstituted C6-C14 arylene. In embodiments, L 9 is a substituted or unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 9 is a substituted C1-C14 alkylene. In embodiments, L 9 is a substituted 2 to 14 membered heteroalkylene. In embodiments, L 9 is a substituted C3-C14 cycloalkylene. In embodiments, L 9 is a substituted 3 to 14 membered heterocycloalkylene. In embodiments, L 9 is a substituted C6-C14 arylene. In embodiments, L 9 is a substituted 5 to 14 membered
• L 9 is an unsubstituted C1-C14 alkylene. In embodiments, L 9 is an unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 9 is an unsubstituted C3- Ci4 cycloalkylene. In embodiments, L 9 is an unsubstituted 3 to 14 membered
• L 9 is an unsubstituted C6-C14 arylene. In embodiments, L 9 is an unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 9 is a substituted or unsubstituted Ci-Cs alkylene. In embodiments, L 9 is a substituted or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 9 is a substituted or unsubstituted C3-C8 cycloalkylene. In embodiments, L 9 is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene.
• L 9 is a substituted or unsubstituted C6-C1 0 arylene. In embodiments, L 9 is a substituted or unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 9 is a substituted Ci-Cs alkylene. In embodiments, L 9 is a substituted 2 to 8 membered heteroalkylene. In embodiments, L 9 is a substituted C3-C8 cycloalkylene. In embodiments, L 9 is a substituted 3 to 8 membered heterocycloalkylene. In embodiments, L 9 is a substituted C6-C1 0 arylene. In embodiments, L 9 is a substituted 5 to 10 membered heteroarylene.
• L 9 is an unsubstituted Ci-Cs alkylene. In embodiments, L 9 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 9 is an unsubstituted C3-C8 cycloalkylene. In embodiments, L 9 is an unsubstituted 3 to 8 membered heterocycloalkylene. In embodiments, L 9 is an unsubstituted C6-C1 0 arylene. In embodiments, L 9 is an unsubstituted 5 to 10 membered heteroarylene.
• L 11 is a bond. In embodiments L 11 is -OC(O)-. In embodiments L 11 is -OC(0)NH-Ph-CH 2 -. In embodiments L 11 is -OC(0)NH-Ph-CH 2 -OC(0)-. In embodiments L 11 is -NH-Ph-CH 2 -. In embodiments L 11 is -NH-Ph-CH 2 -OC(0)-. In embodiments L 11 is -0-Ph-CH 2 -. In embodiments L 11 is -0-Ph-CH 2 -OC(0)-. In embodiment, R 11 is a protein moiety. In embodiment, R 11 is a protein moiety bonded to L 11 through an N of the protein moiety.
• R 11 is a protein moiety bonded to L 11 through an O of the protein moiety. In embodiment, R 11 is a protein moiety bonded to L 11 through an S of the protein moiety. In embodiment, R 11 is a protein moiety bonded to L 11 through an O of a -OC(O)- of the protein moiety. In embodiment, R 11 is a detectable moiety. In embodiment, R 11 is a detectable moiety bonded to L 11 through an N of the detectable moiety. In embodiment, R 11 is a detectable moiety bonded to L 11 through an O of the detectable moiety. In embodiment, R 11 is a detectable moiety bonded to L 11 through an S of the detectable moiety.
• R 11 is a detectable moietv bonded to L 11 through an O of a -OC(O)- of the detectable moiety.
• R 11 is a drug moiety.
• R 11 is a drug moiety bonded to L 11 through an N of the drug moiety.
• R 11 is a drug moiety bonded to L 11 through an O of the drug moiety.
• R 11 is a drug moiety bonded to L 11 through an S of the drug moiety.
• R 11 is a drug moiety bonded to L 11 through an O of a -OC(O)- of the dru moiet .
• L 11 is a substituted or unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 11 is a substituted or unsubstituted C3-C2 0 cycloalkylene. In embodiments, L 11 is a substituted or unsubstituted 3 to 20 membered heterocycloalkylene. In embodiments, L 11 is a substituted or unsubstituted C6-C2 0 arylene. In embodiments, L 11 is a substituted or unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 11 is a substituted C1-C2 0 alkylene.
• L 11 is a substituted 2 to 20 membered heteroalkylene. In embodiments, L 11 is a substituted C3-C20 cycloalkylene. In embodiments, L 11 is a substituted 3 to 20 membered heterocycloalkylene. In embodiments, L 11 is a substituted C6-C2 0 arylene. In embodiments, L 11 is a substituted 5 to 20 membered heteroarylene. In embodiments, L 11 is an unsubstituted C1-C2 0 alkylene. In embodiments, L 11 is an unsubstituted 2 to 20 membered heteroalkylene.
• L 11 is an unsubstituted C3- ⁇ TMTMHnii11TM1 p ne. in embodiments, L 11 is an unsubstituted 3 to 20 membered heterocycloalkylene. In embodiments, L 11 is an unsubstituted C6-C2 0 arylene. In embodiments, L 11 is an unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 11 is a substituted or unsubstituted C1-C14 alkylene. In embodiments, L 11 is a substituted or unsubstituted 2 to 14 membered heteroalkylene.
• L 11 is a substituted or unsubstituted C3-C14 cycloalkylene. In embodiments, L 11 is a substituted or unsubstituted 3 to 14 membered heterocycloalkylene. In embodiments, L 11 is a substituted or unsubstituted C6-C14 arylene. In embodiments, L 11 is a substituted or unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 11 is a substituted C1-C 4 alkylene. In embodiments, L 11 is a substituted 2 to 14 membered heteroalkylene. In embodiments, L 11 is a substituted C3-C 4 cycloalkylene.
• L 11 is a substituted 3 to 14 membered heterocycloalkylene. In embodiments, L 11 is a substituted C6-C14 arylene. In embodiments, L 11 is a substituted 5 to 14 membered heteroarylene. In embodiments, L 11 is an unsubstituted C1-C14 alkylene. In embodiments, L 11 is an unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 11 is an unsubstituted C3- Ci4 cycloalkylene. In embodiments, L 11 is an unsubstituted 3 to 14 membered
• L 11 is an unsubstituted C6-C14 arylene. In embodiments, L 11 is an unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 11 is a substituted or unsubstituted Ci-Cs alkylene. In embodiments, L 11 is a substituted or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 11 is a substituted or unsubstituted C3-C8 cycloalkylene. In embodiments, L 11 is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene.
• L 11 is a substituted or unsubstituted C6-C1 0 arylene. In embodiments, L 11 is a substituted or unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 11 is a substituted Ci-Cs alkylene. In embodiments, L 11 is a substituted 2 to 8 membered heteroalkylene. In embodiments, L 11 is a substituted C3-C8 cycloalkylene. In embodiments, L 11 is a substituted 3 to 8 membered heterocycloalkylene. In embodiments, L 11 is a substituted C6-C1 0 arylene. In embodiments, L 11 is a substituted 5 to 10 membered
• L 11 is an unsubstituted Ci-Cs alkylene. In embodiments, L 11 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 11 is an unsubstituted C3-C8 cycloalkylene. In embodiments, L 11 is an unsubstituted 3 to 8 membered heterocycloalkylene. In embodiments, L 11 is an unsubstituted C6-C1 0 arylene. In embodiments, L 11 is an unsubstituted 5 to 10 membered heteroarylene.
• L 12 is a bond. In embodiments L 12 is -OC(O)-. In embodiments L 12 is -OC(0)NH-Ph-CH 2 -. In embodiments L 12 is -OC(0)NH-Ph-CH 2 -OC(0)-. In embodiments L 12 is -NH-PI1-CH2-. In embodiments L 12 is -NH-Ph-CH 2 -OC(0)-. In embodiments L 12 is -O-Ph- Ho-. Tn embodiments L 12 is -0-Ph-CH 2 -OC(0)-. In embodiment, R 12 is a protein moiety. In embodiment, R is a protein moiety bonded to L through an N of the protein moiety.
• R 12 is a protein moiety bonded to L 12 through an O of the protein moiety. In embodiment, R 12 is a protein moiety bonded to L 12 through an S of the protein moiety. In embodiment, R 12 is a protein moiety bonded to L 12 through an O of a -OC(O)- of the protein moiety. In embodiment, R 12 is a detectable moiety. In embodiment, R 12 is a detectable moiety bonded to L 12 through an N of the detectable moiety. In embodiment, R 12 is a detectable moiety bonded to L 12 through an O of the detectable moiety. In embodiment, R 12 is a detectable moiety bonded to L 12 through an S of the detectable moiety.
• R 12 is a detectable moiety bonded to L 12 through an O of a -OC(O)- of the detectable moiety.
• R 12 is a drug moiety.
• R 12 is a drug moiety bonded to L 12 through an N of the drug moiety.
• R 12 is a drug moiety bonded to L 12 through an O of the drug moiety.
• R 12 is a drug moiety bonded to L 12 through an S of the drug moiety.
• R 12 is a drug moiety bonded to L 12 through an O of a -OC(O)- of the drug moiety.
• L 12 is a substituted or unsubstituted C1-C20 alkylene.
• L 12 is a substituted or unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 12 is a substituted or unsubstituted C3-C2 0 cycloalkylene. In embodiments, L 12 is a substituted or unsubstituted 3 to 20 membered heterocycloalkylene. In embodiments, L 12 is a substituted or unsubstituted C6-C2 0 arylene. In embodiments, L 12 is a substituted or unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 12 is a substituted C1-C2 0 alkylene. In
• L 12 is a substituted 2 to 20 membered heteroalkylene. In embodiments, L 12 is a substituted C3-C20 cycloalkylene. In embodiments, L 12 is a substituted 3 to 20 membered heterocycloalkylene. In embodiments, L 12 is a substituted C6-C2 0 arylene. In embodiments, L 12 is a substituted 5 to 20 membered heteroarylene. In embodiments, L 12 is an unsubstituted C1-C2 0 alkylene. In embodiments, L 12 is an unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 12 is an unsubstituted C3-C2 0 cycloalkylene.
• L 12 is an unsubstituted 3 to 20 membered heterocycloalkylene. In embodiments, L 12 is an unsubstituted C6-C2 0 arylene. In embodiments, L 12 is an unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 12 is a substituted or unsubstituted C1-C14 alkylene. In embodiments, L 12 is a substituted or unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 12 is a substituted or unsubstituted C3-C 4 cycloalkylene.
• L 12 is a substituted or unsubstituted 3 to 14 membered heterocycloalkylene. In embodiments, L 12 is a substituted or unsubstituted C6-C14 arylene. In embodiments, L 12 is a substituted or unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 12 is a substituted C1-C14 alkylene. In
• L 12 is a substituted 2 to 14 membered heteroalkylene. In embodiments, L 12 is a substituted C3-C14 cycloalkylene. In embodiments, L 12 is a substituted 3 to 14 membered heterocycloalkylene. In embodiments, L 12 is a substituted C6-C14 arylene. In embodiments, L 12 is a substituted 5 to 14 membered heteroarylene. In embodiments, L 12 is an unsubstituted C1-C 4 alkylene. In embodiments, L 12 is an unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 12 is an unsubstituted C3-C14 cycloalkylene.
• L 12 is an unsubstituted 3 to 14 membered heterocycloalkylene. In embodiments, L 12 is an unsubstituted C6-C14 arylene. In embodiments, L 12 is an unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 12 is a substituted or unsubstituted Ci-Cs alkylene. In embodiments, L 12 is a substituted or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 12 is a substituted or unsubstituted C3-C8 cycloalkylene. In embodiments, L 12 is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene.
• L 12 is a substituted or unsubstituted C6-C1 0 arylene. In embodiments, L 12 is a substituted or unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 12 is a substituted Ci-Cs alkylene. In embodiments, L 12 is a substituted 2 to 8 membered heteroalkylene. In embodiments, L 12 is a substituted C3-C8 cycloalkylene. In embodiments, L 12 is a substituted 3 to 8 membered heterocycloalkylene. In embodiments, L 12 is a substituted C6-C1 0 arylene. In embodiments, L 12 is a substituted 5 to 10 membered heteroarylene.
• L 12 is an unsubstituted Ci-Cs alkylene. In embodiments, L 12 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 12 is an unsubstituted C3-C8 cycloalkylene. In embodiments, L 12 is an unsubstituted 3 to 8 membered heterocycloalkylene. In embodiments, L 12 is an unsubstituted C6-C1 0 arylene. In embodiments, L 12 is an unsubstituted 5 to 10 membered heteroarylene.
• each L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 may be different.
• L may be referred to as L 132 , L 133 , L 134 , L 135 , L 136 , L 137 , L 138 , L 139 , L 1311 , and L 1312 to refer to L 13 substituents that correlate to L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 , respectively.
• L 14 may be referred to as L 142 , L 143 , L 144 , L 145 , L 146 , L 147 , L 148 , L 149 , L 1411 , and L 1412 to refer to L 14 substituents that correlate to L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 , respectively.
• R 17 may be referred to as R 172 , R 173 , R 174 , R 175 , R 176 , R 177 , R 178 , R 179 , R 1711 , and R 1712 to refer to R 17 substituents that correlate to L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 , respectively.
• L 2 is a bond, -
• L 12 is a bond, - N(R 1712 )-L 1312 -L 1412 -, -N(R 1712 )C(0)0-L 1312 -L 1412 -, -0-L 1312 -L 1412 -, -S-L 1312 -L 1412 -, -OC(0)-L 1312 -L 1412 -, -OC(0)N(R 1712 )-L 1312 -L 1412 -, -OC(0)0-L 1312 -L 1412 -, -OS0 2 -L 1312 -L 1412 -, -C(0)N(R 1712 )-L 132 -L 1412 -, -N(R 1712 )C(0)-L 1312 -L 1412 -, -S(0) 2 N(R 1712 )-L 1312 -L 1412 -, -N(R 1712 )S(0) 2 -L 1312 -L 1412 -, substitute
• each L 13 is independently selected from a bond or substituted or unsubstituted arylene. In embodiments, each L 13 is independently selected from a bond or substituted or unsubstituted phenylene. In embodiments, each L 14 is independently selected from a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene. In embodiments, each L 14 is independently selected from a bond, -(CH 2 ) W -, or -(CH 2 ) w -OC(0)-; and w is an integer between 1 and 4.
• each -L 13 -L 14 - is independently selected from a bond, -Ph-(CH 2 ) W -, or -Ph-(CH 2 ) w -OC(0)-; and w is an integer between 1 and 4.
• -L 13 -L 14 - is a bond.
• -L 13 -L 14 - is -Ph-(CH 2 ) W -.
• -L 13 -L 14 - is— Ph-(CH 2 ) w -OC(0)-. In embodiments, w is 1. In embodiments, w is 2. In embodiments, w is 3. In embodiments, w is 4. In embodiments, -L 13 -L 14 - is
• one or more linkers e.g. L 1 , L 2 ,
• L , L , L , L , L , L , L , L , L , L , L , and/or L ) connected to an R group including a drug moiety, protein moiety, or detectable moiety is -OC(0)NH-Ph-CH 2 -, -OC(0)NH-Ph-CH 2 -OC(0)-, -NH-Ph- CH 2 -, -NH-Ph-CH 2 -OC(0)-, -0-Ph-CH 2 -, or -0-Ph-CH 2 -OC(0)- (collectively "extended linkers").
• L 13 is independently a bond.
• L 13 is independently an unsubstituted arylene.
• L 13 is independently a substituted arylene.
• L 14 is independently a bond.
• L 14 is independently an
• each L 14 is independently an unsubstituted methylene. In embodiments, L 14 is independently an unsubstituted ethylene. In embodiments, L 14 is independently an unsubstituted propylene. In embodiments, L 14 is independently an unsubstituted butylene. In embodiments, each L 14 is independently a -(CH 2 ) -. In embodiments, each L 14 is independently a -(CH 2 ) 2 -. In embodiments, each L 14 is
• each L 14 is independently a -(CH 2 ) 3 -. In embodiments, each L 14 is independently a -(CH 2 ) 4 -. In embodiments, each L 14 is independently a -(CH 2 ) -OC(O)-. In embodiments, each L 14 is independently a -(CH 2 ) 2 -OC(0)-. In embodiments, each L 14 is independently a - iCH -OCYOV. In embodiments, each L 14 is independently a -(CH 2 ) 4 -OC(0)-. [0146] In embodiments, L 13 is -NHC(0)-(CH 2 ) w -NHC(0)0-(CH 2 ) Y1 -.
• L 13 is -NHC(0)-(CH 2 ) w -C(0)NH-(CH 2 ) Y1 -. In embodiments, L 13 is -NHC(0)-(CH 2 ) w -C(0)-. In embodiments, L 13 is -NHC(0)-(CH 2 ) w - NH -. In embodiments, L 13
• L 13 is -NHC(0)-(CH 2 ) w -NHC(0)-. In embodiments, L 13 is -NHC(0)-(CH 2 ) w -C(0)NH-. In embodiments, L 13 is -NHC(0)-(CH 2 ) w -NHC(0)0-. In embodiments, L 13
• L 13 is -NHC(0)-(CH 2 ) W -(OCH 2 CH 2 )TI-C(0)NH-(CH 2 ) y1 -.
• L 13 is -NHC(0)-(CH 2 ) W -(OCH 2 CH 2 )TI-C(0)NH-(CH 2 ) y1 -.
• L 13 is -NHC(0)-(CH 2 ) W -(OCH 2 CH 2 )TI-C(0)NH-(CH 2 )YI-C(0)-.
• L 13 is a substituted or unsubstituted Ci-C 2 o alkylene.
• L 13 is a substituted or unsubstituted 2 to 20 membered heteroalkylene.
• L 13 is a substituted or unsubstituted C3-C 2 o cycloalkylene.
• L 13 is a substituted or unsubstituted 3 to 20 membered heterocycloalkylene.
• L 13 is a substituted or unsubstituted C6-C 2 o arylene.
• L 13 is a substituted or unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 13 is a substituted Ci-C 2 o alkylene. In embodiments, L 13 is a substituted 2 to 20 membered heteroalkylene. In embodiments, L 13 is a substituted C3-C 2 o cycloalkylene. In embodiments, L 13 is a substituted 3 to 20 membered heterocycloalkylene. In embodiments, L 13 is a substituted C6-C 2 o arylene. In embodiments, L 13 is a substituted 5 to 20 membered heteroarylene. In embodiments, L 13 is an unsubstituted Ci-C 2 o alkylene.
• L 13 is an unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 13 is an unsubstituted C3- C 2 o cycloalkylene. In embodiments, L 13 is an unsubstituted 3 to 20 membered
• L 13 is an unsubstituted C6-C 2 o arylene. In embodiments, L 13 is an unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 13 is a substituted or unsubstituted C1-C14 alkylene. In embodiments, L 13 is a substituted or unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 13 is a substituted or unsubstituted C3-C14 cycloalkylene. In embodiments, L 13 is a substituted or unsubstituted 3 to 14 membered heterocycloalkylene.
• L 13 is a substituted or unsubstituted C6-C14 arylene. In embodiments, L 13 is a substituted or unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 13 is a substituted C1-C 4 alkylene. In embodiments, L 13 is a substituted 2 to 14 membered heteroalkylene. In embodiments, L 13 is a substituted C3-C14 cycloalkylene. In embodiments, L 13 is a substituted 3 to 14 membered heterocycloalkylene. In embodiments, L 13 is a substituted C6-C14 arylene. In embodiments, L 13 is a substituted 5 to 14 membered heteroarylene.
• L 13 is an unsubstituted C1-C14 alkylene. In embodiments, L 13 is an unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 13 is an unsubstituted C3- Ci4 cycloalkylene. In embodiments, L 13 is an unsubstituted 3 to 14 membered
• L 13 is an unsubstituted C6-C14 arylene. In embodiments, L is an unsubstituted 5 to 14 membered heteroarylene. In embodiments, L is a substituted or unsubstituted Ci-Cs alkylene. In embodiments, L 13 is a substituted or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 13 is a substituted or unsubstituted C3-C8 cycloalkylene. In embodiments, L 13 is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene.
• L 13 is a substituted or unsubstituted C6-C1 0 arylene. In embodiments, L 13 is a substituted or unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 13 is a substituted Ci-Cs alkylene. In embodiments, L 13 is a substituted 2 to 8 membered heteroalkylene. In embodiments, L 13 is a substituted C3-C8 cycloalkylene. In embodiments, L 13 is a substituted 3 to 8 membered heterocycloalkylene. In embodiments, L 13 is a substituted C6-C1 0 arylene. In embodiments, L 13 is a substituted 5 to 10 membered
• L 13 is an unsubstituted Ci-Cs alkylene. In embodiments, L 13 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 13 is an unsubstituted C3-C8 cycloalkylene. In embodiments, L 13 is an unsubstituted 3 to 8 membered heterocycloalkylene. In embodiments, L 13 is an unsubstituted C6-C10 arylene. In embodiments, L 13 is an unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 13 includes a substituted or unsubstituted cyclooctynyl.
• L 13 includes a substituted cyclooctenyl. In embodiments, L 13 includes a product of a click chemistry reaction. In embodiments, L 13 includes a product of a click chemistry reaction including the product of the reaction of a cyclooctyne and an azide.
• L is -NHC(0)-(CH 2 )W-NHC(0)0-(CH 2 )YI-. In embodiments, L is -NHC(0)-(CH 2 ) w -C(0)NH-(CH 2 ) Y1 -. In embodiments, L
• L 14 is -NHC(0)-(CH 2 ) w -C(0)-. In embodiments, L 14 is -NHC(0)-(CH 2 ) w - NH -. In embodiments, L 14 is -NHC(0)-(CH 2 ) w -NHC(0)-. In embodiments, L 14 is -NHC(0)-(CH 2 ) w -C(0)NH-. In embodiments, L 14 is -NHC(0)-(CH 2 ) w -NHC(0)0-. In embodiments, L 14
• L 14 is -NHC(0)-(CH 2 ) W -(OCH 2 CH 2 )TI-C(0)NH-(CH 2 ) y1 -.
• L 14 is -NHC(0)-(CH 2 ) W -(OCH 2 CH 2 )TI-C(0)NH-(CH 2 ) y1 -.
• L 14 is -NHC(0)-(CH 2 ) W -(OCH 2 CH 2 )TI-C(0)NH-(CH 2 ) Y1 -C(0)-.
• L 14 is a substituted or unsubstituted Ci-C 2 o alkylene.
• L 14 is a substituted or unsubstituted 2 to 20 membered heteroalkylene.
• L 14 is a substituted or unsubstituted C3-C 2 o cycloalkylene.
• L 14 is a substituted or unsubstituted 3 to 20 membered heterocycloalkylene.
• L 14 is a substituted or unsubstituted C6-C 2 o arylene.
• L 14 is a substituted or unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 14 is a substituted Ci-C 2 o alkylene. In embodiments, L 14 is a substituted 2 to 20 membered heteroalkylene. In embodiments, L 14 is a substituted C3-C 2 o cycloalkylene. In embodiments, L 14 is a substituted 3 to 20 membered heterocycloalkylene. In embodiments, L 14 is a substituted C6-C 2 o arylene. In embodiments, L 14 is a substituted 5 to 20 membered heteroarylene. In embodiments, L 14 is an unsubstituted Ci-C 2 o alkylene.
• L 14 is an unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 14 is an unsubstituted C3- C 2 o cycloalkylene. In embodiments, L 14 is an unsubstituted 3 to 20 membered
• L 14 is an unsubstituted C6-C 2 o arylene. In embodiments, L 14 is an unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 14 is a substituted or unsubstituted C1-C14 alkylene. In embodiments, L 14 is a substituted or unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 14 is a substituted or unsubstituted C3-C14 cycloalkylene. In embodiments, L 14 is a substituted or unsubstituted 3 to 14 membered heterocycloalkylene.
• L 14 is a substituted or unsubstituted C6-C14 arylene. In embodiments, L 14 is a substituted or unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 14 is a substituted C1-C 4 alkylene. In embodiments, L 14 is a substituted 2 to 14 membered heteroalkylene. In embodiments, L 14 is a substituted C3-C 4 cycloalkylene. In embodiments, L 14 is a substituted 3 to 14 membered heterocycloalkylene. In embodiments, L 14 is a substituted ( C 14 arylene. In embodiments, L 14 is a substituted 5 to 14 membered heteroarylene.
• L is an unsubstituted C -C alkylene. In embodiments, L is an unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 14 is an unsubstituted C 3 - Ci4 cycloalkylene. In embodiments, L 14 is an unsubstituted 3 to 14 membered
• L 14 is an unsubstituted C6-C14 arylene. In embodiments, L 14 is an unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 14 is a substituted or unsubstituted Ci-Cs alkylene. In embodiments, L 14 is a substituted or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 14 is a substituted or unsubstituted C3-C8 cycloalkylene. In embodiments, L 14 is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene.
• L 14 is a substituted or unsubstituted C6-C1 0 arylene. In embodiments, L 14 is a substituted or unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 14 is a substituted Ci-Cs alkylene. In embodiments, L 14 is a substituted 2 to 8 membered heteroalkylene. In embodiments, L 14 is a substituted C3-C8 cycloalkylene. In embodiments, L 14 is a substituted 3 to 8 membered heterocycloalkylene. In embodiments, L 14 is a substituted C6-C10 arylene. In embodiments, L 14 is a substituted 5 to 10 membered
• L 14 is an unsubstituted Ci-Cs alkylene. In embodiments, L 14 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 14 is an unsubstituted C3-C8 cycloalkylene. In embodiments, L 14 is an unsubstituted 3 to 8 membered heterocycloalkylene. In embodiments, L 14 is an unsubstituted C6-C1 0 arylene. In embodiments, L 14 is an unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 14 includes a substituted or unsubstituted cyclooctynyl.
• L 14 includes a substituted cyclooctenyl. In embodiments, L 14 includes a product of a click chemistry reaction. In embodiments, L 14 includes a product of a click chemistry reaction including the product of the reaction of a cyclooctyne and an azide.
• W is an integer between 0 and 10. W may be an integer between 1 and 10. W may be 0. W may be l. W may be 2. W may be 3. W may be 4. W may be 5. W may be 6. W may be 7. W may be 8. W may be 9. W may be 10. Yl is an integer between 0 and 10. Yl may be an integer between 1 and 10. Yl may be 0. Yl may be 1. Yl may be 2. Yl may be 3. Yl may be 4. Yl may be 5. Yl may be 6. Yl may be 7. Yl may be 8. Yl may be 9. Yl may be 10. Tl is an integer between 0 and 10. Tl may be an integer between 1 and 10. Tl may be 0. Tl may be 1. Tl may be 2. Tl may be 3. Tl may be 4. Tl may be 5. Tl may be 6. Tl may be 7. Tl may be 8. Tl may be 9. Tl may be 10.
• R 2 is hydrogen. In embodiments, R 3 is hydrogen. In embodiments, R 4 is hydrogen. In embodiments, R 5 is hydrogen. In embodiments, R 6 is hydrogen. In
• R 7 is hydrogen.
• R 8 is hydrogen.
• R 9 is hydrogen.
• R is hydrogen. In embodiments, R is hydrogen.
• R 2 is unsubstituted C 1 -C 4 alkyl.
• R 3 is unsubstituted C1-C4 alkyl.
• R 4 is unsubstituted C1-C4 alkyl.
• R 5 is unsubstituted C 1 -C 4 alkyl.
• R 6 is unsubstituted C1-C4 alkyl.
• R 7 is unsubstituted Ci- C4 alkyl.
• R 8 is unsubstituted C1-C4 alkyl.
• R 9 is unsubstituted C1-C4 alkyl.
• R 11 is unsubstituted C1-C4 alkyl.
• R 12 is unsubstituted C1-C4 alkyl.
• R 2 is C2-C4 alkynyl.
• R 3 is C2-C4 alkynyl.
• R 4 is C2-C4 alkynyl.
• R 5 is C2-C4 alkynyl.
• R 6 is C2-C4 alkynyl.
• R 7 is C2-C4 alkynyl.
• R 8 is C2-C4 alkynyl.
• R 9 is C2-C4 alkynyl.
• R 11 is C2-C4 alkynyl. In embodiments, R is C2-C4 alkynyl.
• [01 2 may be J3 mmaayv b bee ..
• R 3 may
• R 6 may be .
• R 7 may be .
• R 8 may be
• R 9 may be .
• R 11 may be .
• R 12 may be [0151]
• the compound has the formula:
• Ring A is a substituted or unsubstituted cycloalkylene or substituted or unsubstituted heterocycloalkylene. Where ring A is "unsubstituted,” Ring A retains the -l ⁇ -R 1 substituent, but is otherwise not substituted. Likewise, where ring A is "substituted,” Ring A includes one or more substituents (e.g. substituent group, size-limited substituent, or lower substituent group as defined above) in addition to the -L ⁇ R 1 substituent.
• substituents e.g. substituent group, size-limited substituent, or lower substituent group as defined above
• L 1 is independently a bond, - N(R 17 )-L 13 -L 14 -, -N(R 17 )C(0)0-L 13 -L 14 -, -0-L 13 -L 14 -, -S-L 13 -L 14 -, -OC(0)-L 13 -L 14 -, -OC(0)N(R 17 )-L 13 -L 14 -, -OC(0)0-L 13 -L 14 -, -OS0 2 -L 13 -L 14 -, -C(0)N(R 17 )-L 13 -L 14 -, -N(R 17 )C(0)-L 13 -L 14 -, -S (0) 2 N(R 17 )-L 13 -L 14 -, -N(R 17 )S(0) 2 -L 13 -L 14 -, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstitute
• biomolecule such as a protein moiety (e.g antibody moiety, peptide moiety, modified peptide moiety such as peptide moiety including folate).
• a protein moiety e.g antibody moiety, peptide moiety, modified peptide moiety such as peptide moiety including folate.
• each L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 may be different.
• L 13 may be referred to as L 131 , L 132 , L 133 , L 13 , T L 135 , T L 136 , T L 137 , T L 138 , T L 139 , T L 1311 , and ⁇ T L 1312 t .o reier t .o T L 13 su ,bst.i ⁇ t.uents that correlate to L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 , respectively.
• L 14 may be referred to as L 141 , L 142 , L 143 , L 144 , L 145 , L 146 , L 147 , L 148 , L 149 , L 1411 , and L 1412 to refer to L 14 substituents that correlate to L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 , respectively.
• R 17 may be referred to as R 171 , R 172 , R 173 , R 174 , R 175 , R 176 , R 177 , R 178 , R 179 , R 1711 , and R 1712 to refer to R 17 substituents that correlate to L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 , respectively.
• L 1 is a bond, - N(R 171 )-L 131 -L 141 -, -N(R 171 )C(0)0-L 131 -L 141 -, -0-L 131 -L 141 -, -S-L 131 -L 141 -, -OC(0)-L 131 -L 141 -, -O C(0)N(R 171 )-L 131 -L 141 -, -OC(0)0-L 131 -L 141 -, -OS0 2 -L 131 -L 141 -, -C(0)N(R 171 )-L 131 -L 141 -, -N(R 171 )C(0)-L 131 -L 141 -, -S(0) 2 N(R 171 )-L 131 -L 141 -, -N(R 171 )S(0) 2 -L 131 -L 141 -,
• ring A is a substituted or unsubstituted divalent radical of adamantane. In embodiments, ring A is a substituted or unsubstituted adamantylene. In embodiments, ring A is an unsubstituted adamantylene. In embodiments, ring A is a substituted or unsubstituted cycloalkylene. In embodiments, ring A is a substituted or unsubstituted C3-C2 0 cycloalkylene. In embodiments, ring A is a substituted or unsubstituted C3-C18 cycloalkylene.
• ring A is a substituted or unsubstituted C3-C16 cycloalkylene. In embodiments, ring A is a substituted or unsubstituted C3-C14 cycloalkylene. In embodiments, ring A is a substituted or unsubstituted C3-C12 cycloalkylene. In embodiments, ring A is a substituted or unsubstituted C3- C1 0 cycloalkylene. In embodiments, ring A is a substituted or unsubstituted C6-C1 0
• ring A is a substituted or unsubstituted Cs-Cio cycloalkylene. In embodiments, ring A is a substituted or unsubstituted 3 to 20 membered heterocycloalkylene. In embodiments, ring A is a substituted or unsubstituted 3 to 18 membered heterocycloalkylene. In embodiments, ring A is a substituted or unsubstituted 3 to 16 membered heterocycloalkylene. In embodiments, ring A is a substituted or unsubstituted 3 to 14 membered heterocycloalkylene.
• ring A is a substituted or unsubstituted 3 to 12 membered heterocycloalkylene. In embodiments, ring A is a substituted or unsubstituted 3 to 10 membered heterocycloalkylene. In embodiments, ring A is a substituted or unsubstituted 6 to 10 membered heterocycloalkylene. In embodiments, ring A is a substituted or unsubstituted 8 to 10 membered heterocycloalkylene.
• -I ⁇ -R 1 is -H.
• R 1 is hydrogen.
• R 1 is a protein moiety.
• R 1 is an antibody moiety.
• R 1 is a drug moiety.
• R 1 is a detectable moiety.
• R 1 is a fluorescent moiety.
• R 1 is a siderophore moiety.
• R 1 is a folate moiety.
• R 1 is an antibody moiety.
• L 1 is a bond.
• L 1 is -OC(O)-.
• L 1 is -OC(0)NH-Ph-CH 2 -.
• L 1 is -OC(0)NH-Ph- CH 2 -OC(0)-.
• L 1 is -NH-Ph-CH 2 -.
• L 1 is -NH-Ph-CH 2 -.
• L 1 is -NH-Ph-CH 2 -.
• L 1 is -NH-Ph-CH 2 -.
• L 1 is -NH-Ph-
• L 1 is -0-Ph-CH 2 -. In embodiments L 1 is -0-Ph-CH 2 -OC(0)-.
• L In embodiments, L 1 is . In embodiments, L 1 is -NHC(0)-(CH 2 ) w -NHC(0)0-(CH 2 ) Y1 -. In embodiments, L 1
• L 1 is -NHr.mvrr.H ) w -C(0)NH-(CH 2 ) Y1 -.
• L 1 is -NHC(0)-(CH 2 ) w -C(0)-.
• L 1 is -NHC(0)-(CH 2 )w- NH -.
• L 1 is -NHC(0)-(CH 2 ) w -NHC(0)-. In embodiments, L 1 is -NHC(0)-(CH 2 ) w -C(0)NH-. In embodiments, L 1 is -NHC(0)-(CH 2 ) w -NHC(0)0-. In embodiments, L 1
• L 1 is -NHC(0)-(CH 2 ) W -(OCH 2 CH 2 )TI-C(0)NH-(CH 2 ) y1 -.
• L 1 is -NHC(0)-(CH 2 ) W -(OCH 2 CH 2 )TI-C(0)NH-(CH 2 ) y1 -.
• L 1 is -NHC(0)-(CH 2 ) W -(OCH 2 CH 2 )TI-C(0)NH-(CH 2 ) Y1 -C(0)-.
• L 1 is a substituted or unsubstituted Ci-C 2 o alkylene.
• L 1 is a substituted or unsubstituted 2 to 20 membered heteroalkylene.
• L 1 is a substituted or unsubstituted C3-C 2 o cycloalkylene.
• L 1 is a substituted or unsubstituted 3 to 20 membered heterocycloalkylene.
• L 1 is a substituted or unsubstituted C6-C 2 o arylene.
• L 1 is a substituted or unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 1 is a substituted Ci-C 2 o alkylene. In embodiments, L 1 is a substituted 2 to 20 membered heteroalkylene. In embodiments, L 1 is a substituted C3-C 2 o cycloalkylene. In embodiments, L 1 is a substituted 3 to 20 membered heterocycloalkylene. In embodiments, L 1 is a substituted C6-C 2 o arylene. In embodiments, L 1 is a substituted 5 to 20 membered
• L 1 is an unsubstituted Ci-C 2 o alkylene. In embodiments, L 1 is an unsubstituted 2 to 20 membered heteroalkylene. In embodiments, L 1 is an unsubstituted C3- C 2 o cycloalkylene. In embodiments, L 1 is an unsubstituted 3 to 20 membered
• L 1 is an unsubstituted C6-C 2 o arylene. In embodiments, L 1 is an unsubstituted 5 to 20 membered heteroarylene. In embodiments, L 1 is a substituted or unsubstituted C1-C14 alkylene. In embodiments, L 1 is a substituted or unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 1 is a substituted or unsubstituted C3-C14 cycloalkylene. In embodiments, L 1 is a substituted or unsubstituted 3 to 14 membered heterocycloalkylene.
• L 1 is a substituted or unsubstituted C6-C14 arylene. In embodiments, L 1 is a substituted or unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 1 is a substituted C1-C14 alkylene. In embodiments, L 1 is a substituted 2 to 14 membered heteroalkylene. In embodiments, L 1 is a substituted C3-C14 cycloalkylene. In embodiments, L 1 is a substituted 3 to 14 membered heterocycloalkylene. In embodiments, L 1 is a substituted C6-C14 arylene. In embodiments, L 1 is a substituted 5 to 14 membered
• L 1 is an unsubstituted C1-C 4 alkylene. In embodiments, L 1 is an unsubstituted 2 to 14 membered heteroalkylene. In embodiments, L 1 is an unsubstituted C3- Ci4 cycloalkylene. In embodiments, L 1 is an unsubstituted 3 to 14 membered
• L 1 is an unsubstituted C6-C14 arylene. In embodiments, L 1 is an unsubstituted 5 to 14 membered heteroarylene. In embodiments, L 1 is a substituted or unsubstituted Ci-Cs alkylene. In embodiments, L 1 is a substituted or unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 1 is a substituted or unsubstituted C3-C8 cycloalkylene. In embodiments, L 1 is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene.
• L 1 is a substituted or unsubstituted C6-C1 0 arylene. In embodiments, L 1 is a substituted or unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 1 is a substituted Ci-Cs alkylene. In embodiments, L 1 is a substituted 2 to 8 membered heteroalkylene. In embodiments, L 1 is a substituted C3-C8 cycloalkylene. In embodiments, L 1 is a substituted 3 to 8 membered heterocycloalkylene. In embodiments, L 1 is a substituted C6-C1 0 arylene. In embodiments, L 1 is a substituted 5 to 10 membered heteroarylene.
• L 1 is an unsubstituted Ci-Cs alkylene. In embodiments, L 1 is an unsubstituted 2 to 8 membered heteroalkylene. In embodiments, L 1 is an unsubstituted C3-C8 cycloalkylene. In embodiments, L 1 is an unsubstituted 3 to 8 membered heterocycloalkylene. In embodiments, L 1 is an unsubstituted C6-C1 0 arylene. In embodiments, L 1 is an unsubstituted 5 to 10 membered heteroarylene. In embodiments, L 1 includes a substituted or unsubstituted cyclooctynyl.
• L 1 includes a substituted cyclooctenyl. In embodiments, L 1 includes a product of a click chemistry reaction. In embodiments, L 1 includes a product of a click chemistry reaction including the product of the reaction of a cyclooctyne and an azide. In embodiments, L 1 is
• L includes
• W is an integer between 0 and 10. W may be an integer between 1 and 10. W may be 0. W may be l. W may be 2. W may be 3. W may be 4. W may be 5. W may be 6. W may be 7. W may be 8. W may be 9. W may be 10. Yl is an integer between 0 and 10. Yl may be an integer between 1 and 10. Yl may be 0. Yl may be 1. Yl may be 2. Yl may be 3. Yl may be 4. Yl may be 5. Yl may be 6. Yl may be 7. Yl may be 8. Yl may be 9. Yl may be 10. Tl is an integer between 0 and 10. Tl may be an integer between 1 and 10. Tl may be 0. Tl may be 1. Tl may be 2. Tl may be 3. Tl may be 4. Tl may be 5. Tl may be 6. Tl may be 7. Tl may be 8. Tl may be 9. Tl may be 10.
• R 1 is a protein moiety bonded to L 1 through an N of the protein moiety. In embodiment, R 1 is a protein moiety bonded to L 1 through an O of the protein moiety. In embodiment, R 1 is a protein moiety bonded to L 1 through an S of the protein moiety. In embodiment, R 1 is a protein moiety bonded to L 1 through an O of a -OC(O)- of the protein moiety. In embodiment, R 1 is a detectable moiety. In embodiment, R 1 is a detectable moiety bonded to L 1 through an N of the detectable moiety. In embodiment, R 1 is a detectable moiety bonded to L 1 through an O of the detectable moiety.
• R 1 is a detectable moiety bonded to L 1 through an S of the detectable moiety. In embodiment, R 1 is a detectable moiety bonded to L 1 through an O of a -OC(O)- of the detectable moiety. In embodiment, R 1 is a drug moiety. In embodiment, R 1 is a drug moiety bonded to L 1 through an N of the drug moiety. In embodiment, R 1 is a drug moiety bonded to L 1 through an O of the drug moiety. In embodiment, R 1 is a drug moiety bonded to L 1 through an S of the drug moiety. In embodiment, R 1 is a drug moiety bonded to L 1 through an O of a -OC(O)- of the drug moiety.
• R 1 is unsubstituted C1-C4 alkyl. In embodiments, R 1 is unsubstituted C2-C4 alkynyl. In embodiment, R 1 is a siderophore moiety. In embodiment, R 1 is a siderophore moiety bonded to L 1 through an N of the siderophore moiety. In embodiment, R 1 is a siderophore moiety bonded to L 1 through an O of the siderophore moiety. In embodiment, R 1 is a siderophore moiety bonded to L 1 through an S of the siderophore moiety.
• R 1 is a siderophore moiety bonded to L 1 through an O of a -OC(O)- of the siderophore moiety.
• R 1 is a ligand for a receptor.
• R 1 is a receptor.
• R 1 is a chelator (e.g., metal chelator, iron chelator).
• R 1 is independently a hydrogen,
• R 1 is
• R 1 is In embodiments, R 1 is
• R 1 is In embodiments,
• R 1 may be .
• R 1 is folate.
• R 1 is a folate moiety.
• R 1 is a folate derivative.
• R 1 is a folate derivative moiety.
• R 1 is a siderophore.
• R 1 is a siderophore moiety.
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 17 are as described herein (e.g. in an aspect, embodiment, example, table, figure, or claim).
• L 2 , L 3 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 are each a bond;
• R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are each hydrogen;
• L 10 is -CH 2 -;
• L 4 is a bond, -
• L 4 is a protein moiety, drug moiety, or a detectable moiety.
• L 4 is a bond, -OC(O)-, -OC(0)NH-
• R 4 is independently a protein moiety.
• R 4 is independently a drug moiety. In embodiment, R 4 is independently a detectable moiety.
• L 2 , L 3 , L 5 , L 7 , L 8 , L 9 , L 11 , and L 12 are each a bond; R 2 , R 3 , R 5 , R 7 , R 8 , R 9 , R 11 , and R 12 are each hydrogen; L 4 and L 6 are independently a bond, -
• R 4 and R 6 are each independently a drug moiety, protein moiety, or detectable moiety.
• L 4 is a drug moiety, protein moiety, or detectable moiety.
• R 4 is independently a protein moiety. In embodiment, R 4 is independently a drug moiety. In embodiment, R 4 is independently a detectable moiety.
• L 6 is a bond, -OC(O)-, -OC(0)NH-Ph- CH 2 -, -OC(0)NH-Ph-CH 2 -OC(0)-, -NH-Ph-CH 2 -, -NH-Ph-CH 2 -OC(0)-, -0-Ph-CH 2 -, or -0-Ph-CH 2 -OC(0)-.
• R 6 is independently a protein moiety.
• R 6 is independently a drug moiety.
• R 6 is independently a detectable moiety.
• L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , and L 12 are each a bond; R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 12 are each hydrogen; L 10 is -N(-L n -R u )-; L 11 is a bond, - N(R 17 )-L 13 -L 14 -, -N(R 17 )C(0)0-L 13 -L 14 -, -0-L 13 -L 14 -, -S-L 13 -L 14 -, -OC(0)-L 13 -L 14 -, -OC(0)N(R 17 )-L 13 -L 14 -, -OC(0)0-L 13 -L 14 -, -OS0 2 -L 13 -L 14 -, -C(0)N(R 17 )-L 13
• L 11 is a bond, -OC(O)-, -OC(0)NH-Ph- CH 2 -, -OC(0)NH-Ph-CH 2 -OC(0)-, -NH-Ph-CH 2 -, -NH-Ph-CH 2 -OC(0)-, -0-Ph-CH 2 -, or -0-Ph-CH 2 -OC(0)-.
• R 11 is independently a protein moiety.
• R 11 is independently a drug moiety.
• R 11 is independently a detectable moiety.
• L 2 , L 3 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 are each a bond; R 2 , R 3 , R 5 , R 7 , R 8 , R 9 , and R 12 are each hydrogen; L 10 is -CH(-R n )-; R 6 and R 11 are joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; L 4 is a bond, - N(R 17 )-L 13 -L 14 -, -N(R 17 )C(0)0-L 13 -L 14 -, -0-L 13 -L 14 -, -S-L 13 -L 14 -, -OC(0)-L 13 -L 14 -, -OC(0)N(
• R 6 and R 11 are joined to form an unsubstituted aryl (it is understood that the unsubstituted aryl is a fused ring that does not include additional substituents beyond the fused ring). In embodiments, R 6 and R 11 are joined to form an unsubstituted phenyl.
• L 4 is a bond, -OC(O)-, -OC(0)NH-Ph-CH 2 -, -OC(0)NH-Ph-
• R 4 is independently a protein moiety. In embodiment, R 4 is independently a drug moiety. In embodiment, R 4 is independently a detectable moiety.
• L 2 , L 3 , L 4 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 are each a bond; R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are each hydrogen; L 10 is -CH 2 -; L 5 is a bond, -
• R 5 is a protein moiety, drug moiety, or a detectable moiety.
• L 5 is a bond, -OC(O)-, -OC(0)NH-Ph- CH 2 -, -OC(0)NH-Ph-CH 2 -OC(0)-, -NH-Ph-CH 2 -, -NH-Ph-CH 2 -OC(0)-, -0-Ph-CH 2 -, or -0-Ph-CH 2 -OC(0)-.
• R 5 is independently a protein moiety.
• R 5 is independently a drug moiety.
• R 5 is independently a detectable moiety.
• L 2 , L 3 , L 4 , L 6 , L 8 , L 9 , L 11 , and L 12 are each a bond; R 2 , R 3 , R 4 , R 6 , R 8 ,
• R 5 is independently a protein moiety. In embodiment, R 5 is independently a drug moiety. In embodiment, R 5 is independently a detectable moiety.
• L 7 is a bond, -OC(O)-, -OC(0)NH-Ph- CH 2 -, -OC(0)NH-Ph-CH 2 -OC(0)-, -NH-Ph-CH 2 -, -NH-Ph-CH 2 -OC(0)-, -0-Ph-CH 2 -, or -0-Ph-CH 2 -OC(0)-.
• R 7 is independently a protein moiety.
• R 7 is independently a drug moiety.
• R 7 is independently a detectable moiety.
• L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , and L 12 are each a bond; R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 12 are each hydrogen; L 10 is -N(-L n -R u )-; L 11 is a bond, -
• R 11 is a drug moiety, protein moiety, or detectable moiety.
• L 11 is a bond, -OC(O)-, -OC(0)NH-Ph- CH 2 -, -OC(0)NH-Ph-CH 2 -OC(0)-, -NH-Ph-CH 2 -, -NH-Ph-CH 2 -OC(0)-, -0-Ph-CH 2 -, or -0-Ph-CH 2 -OC(0)-.
• R 11 is independently a protein moiety.
• R 11 is independently a drug moiety.
• R 11 is independently a detectable moiety.
• L 2 , L 3 , L 4 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 are each a bond; R 2 , R 3 , R 4 , R 6 , R 8 , R 9 , and R 12 are each hydrogen; L 10 is -CH(-R n )-; R 7 and R 11 are joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; L 5 is a bond, - N(R 17 )-L 13 -L 14 -, -N(R 17 )C(0)0-L 13 -L 14 -, -0-L 13 -L 14 -, -S-L 13 -L 14 -, -OC(0)-L 13 -L 14 -, -OC(0)N(
• R 7 and R 11 are joined to form an unsubstituted aryl (it is understood that the unsubstituted aryl is a fused ring that does not include additional substituents beyond the fused ring). In embodiments, R 7 and R 11 are joined to form an unsubstituted phenyl.
• L 5 is a bond, -OC(O)-, -OC(0)NH-Ph-CH 2 -, -OC(0)NH-Ph- CH 2 -OC(0)-, -NH-Ph-CH 2 -, -NH-Ph-CH 2 -OC(0)-, -0-Ph-CH 2 -, or -0-Ph-CH 2 -OC(0)-.
• R 5 is independently a protein moiety.
• R 5 is independently a drug moiety.
• R 5 is independently a detectable moiety.
• the drug moiety is independently a monovalent radical of an anti- infective agent.
• the anti-infective agent is an anti-parasitic drug.
• the anti-infective agent is an anti-bacterial drug.
• the anti- infective agent is an anti-malarial drug.
• the drug moiety is independently a monovalent radical of an anti-cancer agent.
• the detectable moiety is independently a monovalent radical of a fluorophore.
• the protein moiety is independently a monovalent radical of an antibody.
• the drug moiety is a monovalent radical of an anti-cancer agent described herein having an N, O, S, or OC(O) group capable of binding the prodrug moiety (e.g. component of the compounds described herein not including a drug moiety, detectable moiety, or protein moiety).
• the drug moiety is a monovalent radical of an anti-infective agent described herein having an N, O, S, or OC(O) group capable of binding the prodrug moiety (e.g. component of the compounds described herein not including a drug moiety, detectable moiety, or protein moiety).
• the drug moiety is a moiety of a pyrrolo benzodiazepine (e.g.
• tomaymycin carboplatin, CC-1065, CC-1065 analog (e.g. amino-CBIs), nitrogen mustard (such as chlorambucil or melphalan), phosphoroamidate mustard, combretastatin, combretastatin analog, puromycin, centanamycin, gemcitabine, dolastatin, dolastatin analog (including auristatin (e.g.
• monomethyl auristatin E monomethyl auristatin E
• anthracycline antibiotic such as doxorubicin, daunorubicin
• a duocarmycin duocarmycin analog
• enediynes such as neocarzinostatin or calicheamicins
• leptomycin derivaties maytansinoid, maytansinoid analog (e.g. mertansine), methotrexate, mitomycin C, a taxoid, a vinca alkaloid (such as vinblastine or vincristine), epothilones, camptothecin, camptothecin analog, topotecan, or irinotecan.
• the drug moiety is a moiety of amodiaquine, atovaquone, chloroquine, clardribine, clindamycin, cytarabine, daunorubicin, docetaxel, doxorubicin, doxycycline, etoposide, fansidar, fludarabine, halofantrine, idarubicin, imiquimod, irinotecan, mefloquine, methotrexate, mitomycin, oxamniquine, paclitaxel, plicamycin, primaquine, proquanil, pyrimethamine, quinidine, quinine, topotecan, vinblastine, vincristine, KA609, KAF156, tafenoquine, or pyronaridine.
• the drug moiety is a moiety of an anti-bacterial agent described herein. In embodiments, the drug moiety is a moiety of an anti-cancer agent described herein. In embodiments, the drug moiety is a moiety of an antibody or antigen-binding fragment thereof described herein. In embodiments, the drug moiety is a moiety of an antimalarial agent described herein.
• the agent moiety e.g. drug moiety, detectable moiety, protein moiety
• an agent e.g. drug, detectable agent, protein
• an anti-cancer agent or anti- infective agent e.g. antibiotic, anti-parasitic agent, anti-viral agent
• detectable agent e.g.
• agents include amodiaquine, mefloquine, chloroquine, primaquine, imiquimod, oxamniquine, doxycycline, clindamycin, quinine, quinidine, halofantrine, artesunate, fansidar, atovaquone, pyrimethamine, proguanil, vinblastine, vincristine, daunorubicin, docetaxel, paclitaxel, irinotecan, etoposide, doxorubicin, idarubicin, mitomycin, plicamycin, topotecan, clardribine, cytarabine, fludarabine, and methotrexate.
• the agent e.g. drug, detectable agent, protein
• the agent e.g. drug, detectable agent, protein
• the agent e.g. drug, detectable agent, protein
• the agent e.g. drug, detectable agent, protein
• the agent e.g. drug
• the detectable moiety is a moiety of a fluorescent protein, a xanthene derivative (e.g. fluorescein, rhodamine, Oregon green, eosin, or Texas red), cyanine, a cyanine derivative (e.g. cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine or merocyanine), a napththalene derivative (e.g. dansyl or prodan or derivatives), coumarin, a coumarin derivative, an oxadiazole derivative (e.g.
• a xanthene derivative e.g. fluorescein, rhodamine, Oregon green, eosin, or Texas red
• cyanine e.g. cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine or merocyanine
• a napththalene derivative e.g. dans
• pyridyloxazole nitrobenzoxadiazole or benzoxadiazole
• an anthracene derivative e.g. anthraquinones, DRAQ5, DRAQ7, or CyTRAK Orange
• a pyrene derivative e.g. cascade blue and derivatives
• an oxazine derivative e.g. Nile red, Nile blue, cresyl violet, oxazine 170
• an acridine derivative e.g. pro flavin, acridine orange, acridine yellow
• am arylmethine derivative e.g. auramine, crystal violet, malachite green
• tetrapyrrole derivative e.g. porphin, phthalocyanine, bilirubin
• CF dyeTM DRAQTM
• CyTRAKTM CF dyeTM, DRAQTM, CyTRAKTM
• the detectable moiety is a monovalent radical of a detectable agent described herein having an N, O, S, or OC(O) group capable of binding the prodrug moiety (e.g. component of the compounds described herein not including a drug moiety, detectable moiety, or protein moiety). In embodiments, the detectable moiety is a moiety described herein.
• the protein moiety is an antibody moiety.
• the antibody moiety is a moiety of bevacizumab, cetuximab, denosumab, ipilimumab, panitumumab, trastuzumab, or catumaxomab.
• the protein moiety is a monovalent radical of a protein described herein having an N, O, S, or OC(O) group capable of binding the prodrug moiety (e.g. component of the compounds described herein not including a drug moiety, detectable moiety, or protein moiety).
• the protein moiety is a moiety of an antibody, or an antigen-binding fragment thereof, described herein.
• -L u -R u and -L 12 -R 12 are hydrogen.
• -L n -R n is hydrogen.
• -L 12 -R 12 is hydrogen.
• the compound is not a compound including: R 11 and R 12 do not independently include a drug moiety, protein moiety, or detectable moiety; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound including: R 11 and R 12 are not independently a drug moiety, protein moiety, or detectable moiety; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound including: R 11 and R 12 do not independently include a drug moiety, protein moiety, or detectable moiety; R 18 and R 19 are joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, protein moiety, detectable moiety, or drug moiety; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• R 11 and R 12 do not independently include a drug moiety, protein moiety, or detectable moiety
• R 18 and R 19 are joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, protein moiety, detectable moiety, or drug moiety
• the compound is not a compound including: R 11 and R 12 are not independently a drug moiety, protein moiety, or detectable moiety; R 18 and R 19 are joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, protein moiety, detectable moiety, or drug moiety; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound including: R 11 and R 12 do not independently include a drug moiety, protein moiety, or detectable moiety; R 18 and R 19 are joined to form an unsubstituted adamantyl; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound including: R 11 and R 12 are not independently a drug moiety, protein moiety, or detectable moiety; R 18 and R 19 are joined to form an unsubstituted adamantyl; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound wherein R 11 and R 12 do not independently include a drug moiety, protein moiety, or detectable moiety; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound wherein R 11 and R 12 are not independently a drug moiety, protein moiety, or detectable moiety; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound wherein R 11 and R 12 do not independently include a drug moiety, protein moiety, or detectable moiety; R 18 and R 19 are joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, protein moiety, detectable moiety, or drug moiety; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound wherein R 11 and R 12 are not independently a drug moiety, protein moiety, or detectable moiety; R 18 and R 19 are joined to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, protein moiety, detectable moiety, or drug moiety; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound wherein R 11 and R 12 do not independently include a drug moiety, protein moiety, or detectable moiety; R 18 and R 19 are joined to form an unsubstituted adamantyl; L , L , L , L , L , L , and L are bonds; and R , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound wherein R 11 and R 12 are not independently a drug moiety, protein moiety, or detectable moiety; R 18 and R 19 are joined to form an unsubstituted adamantyl; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound wherein R 11 and R 12 do not independently include a drug moiety, protein moiety, or detectable moiety; R 18 and R 19 are joined to form a substituted adamantyl; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• the compound is not a compound wherein R 11 and R 12 are not independently a drug moiety, protein moiety, or detectable moiety; R 18 and R 19 are joined to form a substituted adamantyl; L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , and L 9 are bonds; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are hydrogen.
• R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , and R 19 are independently oxo,
• R -substituted or unsubstituted alkyl R -substituted or unsubstituted heteroalkyl, R - substituted or unsubstituted cycloalkyl, R 20 -substituted or unsubstituted heterocycloalkyl, R 20 - substituted or unsubstituted aryl, or R 20 -substituted or unsubstituted heteroaryl.
• Each R 20 is independently oxo
• Each R 21 is independently oxo
• R -substituted or unsubstituted alkyl R -substituted or unsubstituted heteroalkyl, R - substituted or unsubstituted cycloalkyl, R 22 -substituted or unsubstituted heterocycloalkyl, R 22 - substituted or unsubstituted aryl, or R 22 -substituted or unsubstituted heteroaryl.
• Each R 22 is independently oxo
• L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 10 , L 11 , L 12 , L 13 , and L 14 are independently R 23 -substituted or unsubstituted alkylene, R 23 -substituted or unsubstituted heteroalkylene, R 23 -substituted or unsubstituted cycloalkylene, R 23 -substituted or unsubstituted heterocycloalkylene, R 23 -substituted or unsubstituted arylene, or R 23 -substituted or unsubstituted heteroarylene.
• Each R 23 is independently oxo
• R -substituted or unsubstituted alkyl R -substituted or unsubstituted heteroalkyl, R - substituted or unsubstituted cycloalkyl, R 24 -substituted or unsubstituted heterocycloalkyl, R 24 - substituted or unsubstituted aryl, or R 24 -substituted or unsubstituted heteroaryl.
• Each R 24 is independently oxo
• Each R 25 is independently oxo
• the compound is a compound described herein, including in an example or table.
• R 15 R 24 , and/or R 25 are L 1 , L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 10 , L 11 , L 12 , L 13 , L 14 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , and/or R 25 in an example (e.g. in a compound of table 1, table 2).
• a compound as described herein may include multiple instances of L 13 , L 14 , R 13 , R 14 , R 15 , R 16 , R 17 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , X, protein moiety, drug moiety, 20 detectable moiety and/or other variables.
• each variable may optional be different and be appropriately labeled to distinguish each group for greater clarity.
• each L 13 , L 14 , R 13 , R 14 , R 15 , R 16 , R 17 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , X, protein moiety, drug moiety, and/or detectable moiety is different, they may be referred to, for example, as L 13'1 , L 13'2 ,
• protein moiety protein moiety , protein moiety , protein moiety , protein moiety , protein moiety , protein moiety , protein moiety 14 , protein moiety 15 , protein moiety 16 , protein moiety 11 , protein moiety 18 , protein moiety 19 ,
• detectable moiety detectable moiety , detectable moiety , detectable moiety , detectable moiety 5 , detectable moiety 6 , detectable moiety 1 , detectable moiety 8 , detectable moiety 9 , detectable moiety 10 , detectable moiety 11 , detectable moiety 12 , detectable moiety 13 , detectable moiety 14 , detectable moiety 15 , detectable moiety 16 , detectable moiety 11 , detectable
• detectable moiety detectable moiety , detectable moiety , detectable moiety " , detectable moiety 23 , detectable moiety 24 , detectable moiety 25 , detectable moiety 26 , detectable moiety 27 , detectable moiety 28 , detectable moiety 29 , detectable moiety 30 , detectable moiety 1 ,
• detectable moiety detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety 36 , detectable moiety 37 , detectable moiety 38 , detectable moiety 39 , detectable moiety 40 , detectable moiety 41 , detectable moiety 42 , respectively, wherein the definition of L 13 is assumed by L 131 , L 13 - 2 , L 13 - 3 , L 13 - 4 , L 13 S , L 13'6 , L 13'7 , L 13'8 , L 13'9 , L 1310 , L 1311 , L 1312 , L 1313 , L 1314 , L 131S ,
• L 14 is assumed by L 141 , L 14'2 , L 14'3 , L 14'4 , L 14'5 , L 14'6 , L 14'7 , L 14'8 , L 14'9 , L 1410 , L 1411 , L 1412 , L 1413 ,
• R 13 L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L , L ,
• R 1340 R 1341 , R 13 - 42 the definition of R 14 is assumed by R 14 ⁇ R 142 , R 143 , R 14'4 , R 145 , R 146 , R 147 , R 14 - 8 , R 14 - 9 , R 1410 , R 1411 , R 1412 , R 1413 , R 1414 , R 14'15 , R 14'16 , R 1417 , R 1418 , R 1419 , R 1420 , R 1 21 , R 14 - 22 , R 14'23 , R 14 - 24 , R 14'25 , R 14 - 26 , R 14'27 , R 14 - 28 , R 14'29 , R 14'30 , R 14'31 , R 1432 , R 1433 , R 1434 , R 1435 , R 14 - 36 , R 14'37 , R 14 - 38 , R 14'39 , R 14 - 40 , R 14 -
• R 16 - 42 the definition of R 17 is assumed by R 171 , R 17'2 , R 17'3 , R 17'4 , R 17'5 , R 17'6 , R 17'7 , R 17'8 , R 179 , R 1710 , R 1711 , R 1712 , R 1713 , R 1714 , R 1715 , R 1716 , R 1717 , R 1718 , R 1719 , R 1720 , R 1721 , R 1722 , R 1723 ,
• R 20 J ⁇ 17.37 R 17'38 , R 17'39 , R 1740 , R 17 - 41 , R 1742 , the definition of R 20 is assumed by R 201 , R 20'2 , R 20'3 , R 204 , R 20'5 , r>20.6 D 20.7 D 20.8 r>20.9 D 20.10 D 20.11 D 20.12 D 20.13 D 20.14 D 20.15 D 20.16 D 20.17 D 20.18 D 20.19 D 20.20 , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , K , r>20.21 D 20.22 D 20.23 D 20.24 D 20.25 D 20.26 D 20.27 D 20.
• R 2242 the definition of R 23 is assumed by R 231 , R 23'2 , R 23'3 , R 234 , R 23'5 , R 23'6 , R 23'7 , R 23'8 , R 23'9 , r>23.10 r>23.11 r>23.12 r>23.13 r>23.14 r>23.15 r>23.16 r>23.17 r>23.18 r>23.19 r>23.20 r>23.21 r>23.22 r>23.23 l ⁇ , rv , rv , rv , rv , rv , rv , rv , rv , rv , rv , rv , rv , rv , rv , rv , rv , rv , rv , rv , rv , r
• protein moiety is assumed by protein moiety 1 , protein moiety 2 , protein moiety 3 , protein moiety 4 , 5 protein moiety 5 , protein moiety 6 , protein moiety 7 , protein moiety 8 , protein moiety 9 , protein moiety 10 , protein moiety 11 , protein moiety 12 , protein moiety 13 , protein moiety 14 , protein moiety 1 5 , protein moiety 16 , protein moiety 11 , protein moiety 18 , protein moiety 19 ', protein moiety 20 ,
• detectable moiety is assumed by detectable moiety 1 , detectable moiety 2 , detectable moiety 3 , detectable moiety 4 , detectable moiety 5 , detectable moiety 6 , detectable moiety 7 , detectable moiety 8 , detectable moiety 9 , detectable moiety 10 , detectable moiety n , detectable moiety 12 , detectable moiety 13 , detectable moiety 14 , detectable moiety 15 , detectable moiety 16 , detectable moiety 11 , detectable moiety 18 ,
• detectable moiety detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable
• detectable moiety detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety
• detectable moiety detectable moiety , detectable moiety , detectable moiety , detectable moiety , detectable moiety 41 , detectable moiety 42 .
• R 1 is independently hydrogen, oxo,
• R 26 is independently oxo
• R 5 is independently hydrogen, oxo,
• R 30 is independently oxo
• R 7 is independently hydrogen, oxo,
• R 32 is independently oxo
• R 33 is independently oxo
• R 11 is independently hydrogen, oxo,
• R 12 is independently hydrogen
• R 39 is independently oxo
• R 13 is independently hydrogen
• R 41 is independently 0X0
• R 42 is independently oxo
• R 14 is independently hydrogen
• R 15 is independently hydrogen
• R 48 is independently oxo
• R 16 is independently hydrogen, oxo,
• R 50 is independently oxo
• R 51 is independently oxo
• R 17 is independently hydrogen, oxo,
• R 18 is independently hydrogen, oxo,
• R 57 is independently oxo
• R 19 is independently hydrogen
• R 59 is independently 0X0,
• R 60 is independently oxo
• L 1 is independently a bond, -
• L 1 may be a bond.
• L 1 may be -N(R 171 )-L 131 -L 141 -.
• L 1 may be -N(R 171 )C(0)0-L 131 -L 141 -.
• L 1 may be -0-L 131 -L 141 -.
• L 1 may be -S-L 131 -L 141 -.
• L 1 may be -OC(0)-L 131 -L 141 -.
• L 1 may be -OC(0)N(R 171 )-L 131 -L 141 -.
• L 1 may be -OC(0)0-L 131 -L 141 -.
• L 1 may be -OS0 2 -L 131 -L 141 -.
• L 1 may be -C(0)N(R 171 )-L 131 -L 141 -.
• L 1 may be -OS0 2 -L 131 -L 141 -
• L 1 may be -N(R 171 )C(0)-L 131 -L 141 -.
• L 1 may be -S(0) 2 N(R 171 )-L 131 -L 141 -.
• L 1 may
• L 1 may be -N(R 171 )S(0) 2 -L 131 -L 141 -.
• L 1 may be -C(0)0-L 131 -L 141 -.
• L 1 may be -S0 2 -L 131 -L 141 -.
• L 1 may be -N(H)-.
• L 1 may be -N(H)C(0)0-.
• I ⁇ may be -O-.
• I ⁇ may be -S-.
• L 1 may be -OC(O)-.
• L 1 may be -OC(0)N(H)-.
• L 1 may be -OC(0)0-.
• L 1 may be -OS0 2 -.
• L 1 may be -C(0)N(H)-.
• L 1 may be -N(H)C(0)-.
• L 1 may be -S(0) 2 N(H)-.
• L 1 may be -N(H)S(0) 2 -.
• L 1 may be -C(0)0-.
• L 1 may be -S0 2 -.
• R is independently oxo
• R 63 is independently oxo
• L 5 may be a bond.
• L 5 may be -N(R 175 )-L 135 -L 145 -.
• L 5 may be -N(R 175 )C(0)0-L 135 -L 145 -.
• L 5 may be -0-L 135 -L 145 -.
• L 5 may be -S-L 135 -L 145 -.
• L 5 may be -OC(0)-L 135 -L 145 -.
• L 5 may be -OC(0)N(R 175 )-L 135 -L 145 -.
• L 5 may be -OC(0)0-L 135 -L 145 -.
• L 5 may be -OS0 2 -L 135 -L 145 -.
• L 5 may be -C(0)N(R 175 )-L 135 -L 145 -.
• L 5 may be -C(0)N(R 175 )-L 135 -
• L 5 may be -N(R 175 )C(0)-L 135 -L 145 -.
• L 5 may be -S(0) 2 N(R 175 )-L 135 -L 145 -.
• L 5 may
• L 5 may be -N(R 175 )S(0) 2 -L 135 -L 145 -.
• L 5 may be -C(0)0-L 135 -L 145 -.
• L 5 may be -S0 2 -L 135 -L 145 -.
• L 5 may be -N(H)-.
• L 5 may be -N(H)C(0)0-.
• L 5 may be -0-.
• L 5 may be -S-.
• L 5 may be -OC(O)-.
• L 5 may be -OC(0)N(H)-.
• L 5 may be -OC(0)0-.
• L 5 may be -OS0 2 -.
• L 5 may be -C(0)N(H)-.
• L 5 may be -N(H)C(0)-.
• L 5 may be -S(0) 2 N(H)-.
• L 5 may be -N(H)S(0) 2 -.
• L 5 may
• R 65 is independently oxo
• R 66 is independently oxo,
• L 7 is independently a bond, -
• L may be a bond.
• L may be -N(R )-L -L -.
• L may be -N(R 177 )C(0)0-L 137 -L 147 -.
• L 7 may be -0-L 137 -L 147 -.
• L 7 may be -S-L 137 -L 147 -.
• L 7 may be -OC(0)-L 137 -L 147 -.
• L 7 may be -OC(0)N(R 177 )-L 137 -L 147 -.
• L 7 may be -OC(0)0-L 137 -L 147 -.
• L 7 may be -OS0 2 -L 137 -L 147 -.
• L 7 may be -C(0)N(R 177 )-L 137 -L 147 -.
• L 7 may be -C(0)N(R 177 )-L 137 -L 147 -.
• L 7 may be -N(R 177 )C(0)-L 137 -L 147 -.
• L 7 may be -S(0) 2 N(R 177 )-L 137 -L 147 -.
• L 7 may
• L 7 may be -N(R 177 )S(0) 2 -L 137 -L 147 -.
• L 7 may be -C(0)0-L 137 -L 147 -.
• L 7 may be -S0 2 -L 137 -L 147 -.
• L 7 may be -N(H)-.
• L 7 may be -N(H)C(0)0-.
• L 7 may be -0-.
• L 7 may be -S-.
• L 7 may be -OC(O)-.
• L 7 may be -OC(0)N(H)-.
• L 7 may be -OC(0)0-.
• L 7 may be -OS0 2 -.
• L 7 may be -C(0)N(H)-.
• L 7 may be -N(H)C(0)-.
• L 7 may be -S(0) 2 N(H)-.
• L 7 may be -N(H)S(0) 2 -.
• L 7 may
• R 68 is independently oxo
• R 69 is independently oxo
• L 11 may be -N(R 1711 )-L 1311 -L 1411 -.
• L 11 may be -N(R 1711 )C(0)0-L 1311 -L 1411 -.
• L 11 may be -0-L 1311 -L 1411 -.
• ⁇ may be -S-L 1311 -!.
• 1411 L 11 may be -OC(0)-L 1311 -L 1411 -.
• L 11 may
• L 11 may be -OC(0)N(R 1711 )-L 1311 -L 1411 -.
• L 11 may be -OC(0)0-L 1311 -L 1411 -.
• L 11 may
• L 11 may be -OS0 2 -L 1311 -L 1411 -.
• L 11 may be -C(0)N(R 1711 )-L 1311 -L 1411 -.
• L 11 may
• L H ⁇ may be - oS(0) 2 ⁇ N ⁇ /( ⁇ R 1711 )- T L 1311 - T L 1411 -.
• T L 11 m may
• L H may be - cS0 ⁇ 1311
• L 11 may be -N(H)-.
• L 11 may be -N(H)C(0)0-.
• L u may be -0-.
• L n may be -S-.
• L 11 may be -OC(O)-.
• L 11 may be -OC(0)N(H)-.
• L 11 may be -OC(0)0-.
• L 11 may be -OS0 2 -.
• L 11 may be -C(0)N(H)-.
• L 11 may be -N(H)C(0)-.
• L 11 may be -S(0) 2 N(H)-.
• L 11 may be -N(H)S(0) 2 -.
• L 11 may be -C(0)0-.
• L 11 may be -S0 2 -.
• R 71 is independently oxo
• L 12 is independently a bond, -
• L 12 may be -N(R 1712 )-L 1312 -L 1412 -.
• L 12 may be -N(R 1712 )C(0)0-L 1312 -L 1412 -.
• L 12 may be -0-L 1312 -L 1412 -.
• L 12 may be -S-L 1312 -L 1412 ,
• L 12 may be -OC(0)-L 1312 -L 1412 -.
• L 12 may
• ⁇ L 12 m may , be - oS(0) 2 ⁇ N ⁇ /( ⁇ R 1712 ⁇ )- ⁇ L 1312 - ⁇ L 1412 -.
• ⁇ L 12 m may
• L 1312 - ⁇ L 1412 L 12 may be -N(H)-.
• L 12 may be -N(H)C(0)0-.
• L 12 may be -0-.
• L 12 may be -S-.
• L 12 may be -OC(O)-.
• L 12 may be -OC(0)N(H)-.
• L 12 may be -OC(0)0-.
• L 12 may be -OS0 2 -.
• L 12 may be -C(0)N(H)-.
• L 12 may be -N(H)C(0)-.
• L 12 may be -S(0) 2 N(H)-.
• L 12 may be -N(H)S(0) 2 -.
• L 12 may be -C(0)0-.
• L 12 may be -S0 2 -.
• R 74 is independently oxo,
• R 75 is independently oxo
• L 13 is independently a bond, -
• L 13 may be a bond.
• L 13 may be -N(H)-.
• L 13 may be -N(H)C(0)0-.
• L 13 may be -0-.
• L 13 may be -S-.
• L 13 may be -OC(O)-.
• L 13 may
• L 13 may be -OC(0)N(H)-.
• L 13 may be -OC(0)0-.
• L 13 may be -OS0 2 -.
• L 13 may be -C(0)N(H)-.
• L 13 may be -N(H)C(0)-.
• L 13 may be -S(0) 2 N(H)-.
• L 13 may be -N(H)S(0) 2 -.
• L 13 may be -C(0)0-.
• L 13 may be -S0 2 -.
• R 77 is independently oxo
• R 78 is independently oxo
• L 14 may be a bond.
• L 14 may be -N(H)-.
• L 14 may be -N(H)C(0)0-.
• L 14 may be -0-.
• L 14 may be -S-.
• L 14 may be -OC(O)-.
• L 14 may
• L 14 may be -OC(0)N(H)-.
• L 14 may be -OC(0)0-.
• L 14 may be -OS0 2 -.
• L 14 may be -C(0)N(H)-.
• L 14 may be -N(H)C(0)-.
• L 14 may be -S(0) 2 N(H)-.
• L 14 may be -N(H)S(0) 2 -.
• L 14 may be -C(0)0-.
• L 14 may be -S0 2 -.
• R 80 is independently oxo
• R 28 , R 31 , R 34 , R 37 , R 40 , R 43 , R 46 , R 49 , R 52 , R 55 , R 58 , R 61 , R 64 , R 67 , R 70 , R 73 , R 76 , R 79 , and R 82 are independently hydrogen, oxo,
• the compound is in a pharmaceutically acceptable salt.
• the compound is not in a pharmaceutically acceptable salt.
• the compound is co-administered with a second agent (e.g. therapeutic agent).
• the second agent is administered in a therapeutically effective amount.
• the second agent is an agent for treating an infectious disease.
• the second agent is an agent for treating a parasitic disease.
• the second agent is an agent for treating malaria.
• the second agent is an agent for treating cancer.
• the second agent is an agent for treating solid tumors.
• the second agent is an agent for treating hematological cancers.
• the second agent is an agent for treating diseases characterized by an increased level of iron relative to a control (e.g.
• the second agent is an agent for treating diseases characterized by an increased level of a reductant (e.g. biological reductant, iron) relative to a control (e.g. subject without the disease or sample from a subject without the disease).
• a reductant e.g. biological reductant, iron
• Non-limiting examples of prodrug formulae described herein are shown below, wherein (-X-AGENT) represent R groups as described herein (e.g. R 4 , R 5 , R 6 , R 7 , R 11 , or R 12 ).
• each (-X-AGENT) is independently a drug moiety, detectable moiety, or protein moiety.
• the compound is a compound described herein or a compound having the formula of a compound described herein, including in the examples section below and in the
• a pharmaceutical composition including a pharmaceutically acceptable excipient and a compound described herein (including in an aspect, embodiment, table, example, or claim), or a pharmaceutically acceptable salt thereof.
• the pharmaceutical composition includes a compound, or pharmaceutically acceptable salt thereof, as described herein (e.g. compound of formula I, or any embodiment thereof) in a therapeutically effective amount.
• the pharmaceutical composition includes a second agent (e.g. therapeutic agent).
• the pharmaceutical composition includes a second agent in a therapeutically effective amount.
• the second agent is an agent for treating cancer.
• the second agent is an agent for treating an infectious disease. In embodiments, the second agent is an agent for treating a bacterial disease. In embodiments, the second agent is an agent for treating a parasitic disease. In embodiments, the second agent is an agent for treating malaria. In embodiments, the second agent is an anti-cancer agent. In embodiments, the second agent is an anti-infective agent. In embodiments, the second agent is an anti-parasitic agent. In embodiments, the second agent is an anti-malarial agent. In embodiments, the second agent is an agent for treating solid tumors. In embodiments, the second agent is an agent for treating hematological cancers.
• the second agent is an agent for treating diseases characterized by an increased level of iron relative to a control (e.g. subject without the disease or sample from a subject without the disease).
• the second agent is an agent for treating diseases characterized by an increased level of reductant (e.g. biological reductant, Fe 11 ) relative to a control (e.g. subject without the disease or sample from a subject without the disease).
• reductant e.g. biological reductant, Fe 11
• a method of treating a disease in a patient in need of such treatment including administering a therapeutically effective amount of a compound described herein (including in an aspect, embodiment, table, example, or claim), or a pharmaceutically acceptable salt thereof, to the patient.
• a compound as described herein including in an aspect, embodiment, table, example, or claim
• a pharmaceutically acceptable salt thereof for use in the treatment of a disease in a subject.
• the use may include administering to the subject a compound described herein.
• the use may include administering to the subject a therapeutically effective amount of a compound described herein.
• a pharmaceutical composition as described herein for use in the treatment of a disease in a subject.
• a compound as described herein for use in the manufacture of a medicament for treatment of a disease in an aspect, is provided a pharmaceutical composition as described herein for use in the manufacture of a medicament for treatment of a disease.
• the disease is associated with a cell or organism having an increased level of a reductant (e.g. biological reductant, Fe 11 ) compared to a standard control (e.g. subject without the disease or sample from a subject without the disease).
• a standard control e.g. subject without the disease or sample from a subject without the disease.
• the disease is associated with a cell or organism having an increased Fe 11 level compared to a standard control (e.g. subject without the disease or sample from a subject without the disease).
• the method of treating is a method of preventing.
• Drug moieties that form part of the prodrugs described herein obtain functionality due to chemical changes in the prodrugs that occur under physiological conditions.
• the trioxane or trioxolane ring moiety of prodrugs described herein i.e. compounds described herein
• the ketone then undergoes a beta-elimination reaction to release the agent (e.g. drug, detectable agent, protein, sideropohore, antibody) and a new ketone containing compound.
• the agent e.g. drug, detectable agent, protein, sideropohore, antibody
• the drug, detectable agent, protein, sideropohore, antibody obtained from the prodrug due to chemical changes under physiological conditions may be capable of use in treating or detecting mammalian disease caused by a cell or organism having increased reductant (e.g. biological reductant, Fe 11 ) levels compared to reductant (e.g. biological reductant, Fe 11 ) levels in mammalian plasma.
• reductant e.g. biological reductant, Fe 11
• reductant e.g. biological reductant, Fe 11
• the agent e.g. drug, detectable agent, protein, sideropohore, antibody obtained from the prodrug due to chemical changes under physiological conditions may be capable of use in treating or detecting mammalian disease caused by a cell or organism having increased Fe 11 levels compared to Fe 11 levels in mammalian plasma.
• the mammalian disease may be a human disease.
• the human disease may be a parasitic disease or a cancer.
• the disease may be malaria, schistosomiasis, trypanosomiasis, leukemia, cervical cancer, breast cancer, colon cancer, ovarian cancer, prostate cancer, thyroid cancer, lung cancer, glioblastoma, or melanoma.
• the disease may be a cancer where transferrin receptors (CD71) are over-expressed as compared to normal cells.
• the disease may be a bacterial disease.
• the disease may be an infectious disease.
• the prodrug compounds can be employed in methods to treat a disease that is associated with a cell or organism that has increased reducant (e.g. biological reducant, Fe 11 ) levels compared to reducant (e.g. biological reducant, Fe 11 ) levels in the same location in a mammal without the disease (e.g. in mammalian plasma).
• reducant e.g. biological reducant, Fe 11
• reducant e.g. biological reducant, Fe 11
• a compound as described herein (including in an aspect, embodiment, table, example, or claim), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease that is associated with a cell or organism that has increased reducant (e.g. biological reducant, Fe 11 ) levels compared to reducant (e.g. biological reducant, Fe 11 ) levels in the same location in a mammal without the disease (e.g. in mammalian plasma).
• reducant e.g. biological reducant, Fe 11
• reducant e.g. biological reducant, Fe 11
• the use may include administering to the subject a compound described herein.
• the use may include administering to the subject a therapeutically effective amount of a compound described herein.
• a pharmaceutical composition as described herein for use in the treatment of a disease that is associated with a cell or organism that has increased reducant (e.g. biological reducant, Fe 11 ) levels compared to reducant (e.g. biological reducant, Fe 11 ) levels in the same location in a mammal without the disease (e.g. in mammalian plasma).
• reducant e.g. biological reducant, Fe 11
• reducant e.g. biological reducant, Fe 11
• reducant e.g. biological reducant, Fe 11
• reducant e.g. biological reducant, Fe 11
• the method or use may include administering an effective amount of the prodrug compound (or pharmaceutical formulation thereof) to a patient in need of such treatment.
• Increased reducant (e.g. biological reducant, Fe 11 ) levels are levels (e.g. cellular) of reducant (e.g. biological reducant, Fe 11 ) that are sufficiently high to cause disease in a patient and/or are higher than in the plasma of a patient.
• the method or use includes administering an effective amount of a prodrug compound and a reducant (e.g. biological reducant, Fe 11 ) containing agent to a patient in need of such treatment.
• the reducant (e.g. biological reducant, Fe ) containing agent may be co-administered with the prodrug (compound described herein, including formula I and embodiments).
• the reducant e.g.
• a disease that is associated with a cell or organism that has increased reducant (e.g. biological reducant, Fe 11 ) levels refers to a disease in which reducant (e.g. biological reducant, Fe 11 ) levels are elevated relative to reducant (e.g. biological reducant, Fe 11 ) 1 levels in the cell or organism in the absence of the disease.
• reducant e.g. biological reducant, Fe 11
• reducant e.g. biological reducant, Fe 11
• reducant e.g. biological reducant, Fe 11
• reducant e.g. biological reducant, Fe 11
• reducant e.g. biological reducant, Fe 11
• reducant e.g. biological reducant, Fe 11
• the increased reducant (e.g. biological reducant, Fe 11 ) levels are the result of the disease.
• the increased reducant (e.g. biological reducant, Fe 11 ) levels are the result of the disease, and additionally the increased reducant (e.g. biological reducant, Fe 11 ) levels may cause symptoms related to increased reducant (e.g. biological reducant, Fe 11 ) levels.
• the prodrug compounds (compound described herein, including formula I and embodiments) can be employed in methods to treat a disease that is associated with a cell or organism that has increased Fe 11 levels compared to Fe 11 levels in mammalian plasma.
• a compound as described herein (including in an aspect, embodiment, table, example, or claim), or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease that is associated with a cell or organism that has increased Fe 11 levels compared to Fe 11 levels in mammalian plasma.
• the use may include administering to the subject a compound described herein.
• the use may include administering to the subject a
• a pharmaceutical composition as described herein for use in the treatment of a disease that is associated with a cell or organism that has increased Fe 11 levels compared to Fe 11 levels in mammalian plasma.
• a compound as described herein for use in the manufacture of a medicament for treatment of a disease that is associated with a cell or organism that has increased Fe 11 levels compared to Fe 11 levels in mammalian plasma In an aspect is provided a pharmaceutical composition as described herein for use in the manufacture of a medicament for treatment of a disease that is associated with a cell or organism that has increased Fe 11 levels compared to Fe 11 levels in mammalian plasma.
• the method or use may include administering an effective amount of the prodrug compound (or pharmaceutical formulation thereof) to a patient in need of such treatment.
• Increased Fe 11 levels are cellular levels of Fe 11 that are sufficiently high to cause disease in a patient and are higher than in the plasma of a patient.
• the method or use includes administering an effective amount of a prodrug compound and an Fe 11 containing agent to a patient in need of such treatment.
• the Fe 11 containing agent is ferroglycine sulfate or transferrin.
• the Fe 11 containing agent may be co-administered with the prodrug (compound described herein, including formula I and embodiments).
• the Fe 11 containing agent may be administered before or after prodrug
• a disease that is associated with a cell or organism that has increased Fe 11 levels compared to Fe 11 levels in mammalian plasma refers to a disease in which Fe 11 levels are elevated relative to Fe 11 levels in mammalian plasma in the absence of the disease.
• the disease associated with increased Fe 11 levels is not bound by any particular mechanistic theory, and include those diseases resulting in increase Fe 11 levels and/or caused by Fe 11 levels.
• the increased Fe 11 levels are the result of the disease. In some embodiments, the increased Fe 11 levels are the result of the disease, and additionally the increased Fe 11 levels cause symptoms related to increased Fe 11 levels.
• a method of identifying a patient having a disease associated with a cell or organism having an increased reducant (e.g. biological reducant, Fe 11 ) level compared to a standard control including administering an effective amount of a compound described herein (including in an aspect, embodiment, table, example, or claim), or a pharmaceutically acceptable salt thereof, to the patient.
• the method may include detecting the presence of the compound.
• the method may include detecting an increased level of the compound or detectable agent compared to the level of compound or detectable agent detected in a patient without the disease.
• a compound as described herein (including in an aspect, embodiment, table, example, or claim), or a pharmaceutically acceptable salt thereof, for use in identifying a patient having a disease associated with a cell or organism having an increased reducant (e.g. biological reducant, Fe 11 ) level compared to a standard control.
• the use may include administering to the subject a compound described herein.
• the use may include administering to the subject an effective amount of a compound described herein.
• a method of identifying a patient having a disease associated with a cell or organism having an increased Fe 11 level compared to a standard control including administering an effective amount of a compound described herein (including in an aspect, embodiment, table, example, or claim), or a pharmaceutically acceptable salt thereof, to the patient.
• a compound as described herein (including in an aspect, embodiment, table, example, or claim), or a pharmaceutically acceptable salt thereof, for use in identifying a patient having a disease associated with a cell or organism having an increased Fe 11 level compared to a standard control.
• the use may include administering to the subject a compound described herein.
• the use may include administering to the subject an effective amount of a compound described herein.
• the method or use may include detecting the presence of the compound.
• the method or use may include detecting an increased level of the compound or detectable agent compared to the level of compound or detectable agent detected in a patient without the disease.
• the compound includes a detectable moiety.
• the detectable moiety is a flurorescent moiety.
• the detectable moiety is a moiety of a fluorescent dye, electron-dense reagent, enzyme (e.g., as commonly used in an ELISA), biotin, digoxigenin, paramagnetic molecule, paramagnetic nanoparticle, ultrasmall superparamagnetic iron oxide (“USPIO”) nanoparticle, USPIO nanoparticle aggregate, nanoparticle contrast agent, liposome or other delivery vehicle containing Gadolinium chelate (“Gd-chelate”) molecules, Gadolinium, radioisotope (e.g. 32 P), radionuclide (e.g.
• cyanine indocarbocyanine, oxacarbocyanine, thiacarbocyanine or merocyanine
• napththalene derivative e.g. dansyl or prodan derivative
• coumarin or a derivative oxadiazole derivative (e.g. pyridyloxazole, nitrobenzoxadiazole or benzoxadiazole), anthracene derivative (e.g. anthraquinone, DRAQ5, DRAQ7, or CyTRAK Orange), , pyrene derivative (e.g. cascade blue or derivative), oxazine derivative (e.g.
• Nile red, Nile blue, cresyl violet, oxazine 170 Nile red, Nile blue, cresyl violet, oxazine 170
• acridine derivative e.g. pro flavin, acridine orange, acridine yellow
• arylmethine derivative e.g. auramine, crystal violet, malachite green
• tetrapyrrole derivative e.g. porphin, phthalocyanine, bilirubin
• CF dyeTM, DRAQTM acridine derivative
• acridine derivative e.g. pro flavin, acridine orange, acridine yellow
• arylmethine derivative e.g. auramine, crystal violet, malachite green
• tetrapyrrole derivative e.g. porphin, phthalocyanine, bilirubin
• CF dyeTM DRAQTM
• CyTRAKTM BODIPYTM, Alexa FluorTM, DyLight FluorTM, AttoTM, TracyTM, FluoProbeTM, Abberior DveTM.
• a detectable agent e.g. fluorescent agent
• a detectable agent e.g. fluorescent agent
• a detectable agent e.g. fluorescent agent
• the present invention provides a method of detecting a detectable agent (e.g. fluorescent agent) in a sample from an organism, by administering a compound described herein to the sample from an organism, allowing the sample to metabolize the compound thereby producing a detectable agent (e.g fluorescent agent), and detecting the detectable agent (e.g. fluorescent agent) in the sample.
• a detectable agent e.g. fluorescent agent
• L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , L 11 , and L 12 are independently a bond, - N(R 17 )-L 13 -L 14 -, -N(R 17 )C(0)0-L 13 -L 14 -, -0-L 13 -L 14 -, -S-L 13 -L 14 -, -OC(0)-L 13 -L 14 -, -OC(0)N(R 17 )-L 13 -L 14 -, -OC(0)0-L 13 -L 14 -, -OS0 2 -L 13 -L 14 -, -C(0)N(R 17 )-L 13 -L 14 -, -N(R 17 )C(0)-L 13 -L 14 -, -S (0) 2 N(R 17 )-L 13 -L 14 -, -N(R 17 )S(0) 2 -L 13 -L 14
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are independently hvdroeen.
• Ring A is a substituted or unsubstituted cycloalkylene or substituted or unsubstituted heterocycloalkylene; R 1 is hydrogen,
• R 5 is a protein moiety, drug moiety, or a detectable moiety.
• R 5 and R 7 are each independently a drug moiety, protein moiety, or detectable moiety.
• L 2 , L 3 , L 4 , L 5 , L 6 , L 7 , L 8 , L 9 , and L 12 are a bond;
• R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 12 are hydrogen;
• L 10 is -N(-L n -R n )-;
• L 11 is a bond, -
• R 11 is a drug moiety, protein moiety, or detectable moiety.
• R 5 is a drug moiety, protein moiety, or detectable moiety.
• each L 13 is independently selected from a bond or substituted or unsubstituted arylene.
• each L 13 is independently selected from a bond or substituted or unsubstituted phenylene.
• each L 14 is independently selected from a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
• 26 The compound of embodiment 25, wherein each L 14 is independently selected from a bond, -(CH 2 ) W -, or -(CH 2 ) w -OC(0)-; w is an integer between 1 and 4.
• a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of one of embodiments 1 to 38.
• a method of treating a disease in a patient in need of such treatment comprising administering a therapeutically effective amount of a compound of one of embodiments 1 to 38 to said patient.
• a method of identifying a patient having a disease associated with an increased reductant level compared to a standard control comprising obtaining a biological sample from said patient, contacting said biological sample with an effective amount of a compound of one of embodiments 1 to 38, wherein said compound comprises a detectable moiety, detecting an increased level of said detectable moiety or a detectable agent resulting from cleavage of said detectable moiety relative the level of said detectable moiety or detectable agent in the standard control.
• Step 1 Preparation of ketone Cmpd la, 3 -[(tert-butyldiphenylsilyl)oxy] cyclohexan -1 -one
• the mixture was cooled at 0 °C while ozone was bubbled through the solution (0.6 L/min, 30% power). After 10 min of reaction, an additional portion of oxime was added (0.100 g, 0.558 mmol, 0.74 equiv) and bubbling of ozone was continued for an additional 20 min (30 min total reaction time). The reaction mixture was sparged with 0 2 at 0 °C for 5 min, and with argon while warming to rt over 10 min. The reaction mixture was then concentrated to afford a colorless oil.
• Step 3 Preparation of alcohol Cmpd lc, tert-butyl( ⁇ dispiro[adamantane-2,2'-[l,3,5]trioxolane- 4', 1 " -cyclohexane] -3 " -yloxy ⁇ )diphenylsilane H
• the reaction was stirred at rt for another 1 h. Another portion of TBAF (1.0 M in THF, 2.0 mL, 2.0 mmol, 2.6 equiv) added. The reaction was stirred at rt for 1 h. The reaction mixture was concentrated to ca 5 mL and stirring was continued at rt for 1 h. The reaction mixture was diluted with 30 mL of EtOAc and 20 mL of H 2 0 and 5 mL satd aq NaCl solution. The aqueous layer was separated and extracted with three 20-mL portions of EtOAc.
• Step 4 Preparation of carbamate Cmpd 1.
• a 20-mL, scintillation vial equipped with a screw cap and stirbar was charged with alcohol Cmpd lc (0.060 g, 0.210 mmol, 1.0 equiv), toluene (1 mL), pyridine (20 ⁇ , 0.210 mmol, 1 equiv), and 2,5-dichlorophenyl isocyanate (0.080 g, 0.430 mmol, 2 equiv).
• the reaction mixture was stirred at rt for 18 h.
• the resulting cloudy reaction mixture was filtered with the aid of 50 mL of EtOAc.
• the filtrate was washed with 20 mL of H 2 O.
• aqueous layer was extracted with three 20-mL portions of EtOAc.
• the combined organic phases were washed with 20 mL of satd aq NaCl solution, dried over MgS0 4 , filtered, and concentrated to a yellow oil.
• Step 1 Preparation of trioxolane Cmpd 2a, trispiro[adamantane-2,2'-[l,3,5Jtrioxolane-4',l "- cyclohexane -3", 2 ""-[1,3 Jdioxolane]
• Step 3 Preparation of alcohol Cmpd 2c, 3"-ethenyldispiro[adamantane-2,2'-[l,3,5]trioxolane- 4', 1 "-cyclohexane]-3"-ol
• ⁇ ⁇ was AA PA dropwise via syringe and the reaction mixture was stirred at -78 °C for 10 min. Another protion of vinyl magnesium bromide (1.0 M in THF, 4.0 mL, 4.0 mmol, 14 equiv) was added dropwise via syringe and the reaction mixture was stirred at -78 °C for 45 min. The reaction mixture was then diluted with 20 mL of Et 2 0 and 20 mL of satd aq NH 4 C1 solution. The aqueous layer was separated and extracted with three 20-mL portions of Et 2 0. The combined organic phases were washed with 30 mL of satd aq NaCl solution, dried over MgS0 4 , fltered, and concentrated to afford a cloudy, pale-yellow oil. Purification via column
• the resulting precipitate was removed via filtration through a 1.5" x 2" pad of Celite with the aid of 20 mL of Et 2 0 and 10 mL of H 2 O.
• the aqueous phase of the filtrate was separated and extracted with three 20-mL portions of Et 2 0.
• the combined organic phases were washed with 30 mL of satd aq NaCl solution, dried over MgS0 4 , filtered and concentrated to afford a cloudy oil.
• Step 1 Preparation of trioxolane Cmpd 3a, tert-butyl[(3"S,5"S)-5"-tert-butyldispiro[adamantane- 2,2'-[l,3,5]trioxolane-4', l"-cyclohexane]-3"-yloxy]dimethylsilane
• Step 2 Preparation of Cmpd 3b, (3"S*,5"S*) -5"-tert-butyldispiro[adamantane-2,2'- [1,3, 5]trioxolane -4 ', 1 " -cyclohexane] -3"-ol
• Step 1 Preparation of Cmpd 4a, 3" -(acetyloxy)dispiro [adamantane-2,2' -[ 1 ,3,5] trioxolane-4', ⁇ ' - cyclohexane] -5"-yl acetate
• Step 2 Preparation of Cmpd 4b, (3"R*,5"S*) -dispiro[adamantane-2,2'-[l,3,5]trioxolane-4',l "- cyclohexane] -3",5"-diol
• the reaction mixture was treated with an additional 2,5-dichlorophenyl isocyanate (0.040 g, 0.219 mmol, 5 equiv) and heated to 50 °C for 2 h. Additional 2,5- dichlorophenyl isocyanate (0.100 g, 0.532 mmol, 12 equiv) and DMAP (0.020 g, 0.2 mmol, 3.7 equiv) were added and the reaction mixture was stirred at 50 °C for 29 h. The reaction mixture was diluted with 20 mL of EtOAc and 15 mL of 3 ⁇ 40 and the resulting slurry was filtered through a 2" x 2" pad of Celite.
• the aqueous layer was separated and extracted with three 20-mL portions of CH2CI2.
• the combined organic phases were washed with 30 mL of satd aq NaCl solution, dried over MgS0 4 , filtered, and concentrated to afford a pale yellow oil.
• Step 1 Preaparation of p-nitrophenyl carbonate Cmpd 6a (dispirofadamantane-2,2'- [ 1, 3, 5]trioxolane -4 ', 1 " -cyclohexane] -3 "-yl 4 -nitrophenyl carbonate
• Step 2 Preparation of Cmpd 6, [0335] A 20-mL, scintillation vial equipped with stirbar and screw cap was charged with a solution of carbonate Cmpd 6a (0.058 g, 0.13 mmol, 1 equiv) in DMF (1 mL) and N,N- diisopropylethylamine (60 ⁇ , 0.33 mmol, 2.5 equiv). Mefloquine hydrochloride (0.081 g, 0.195 mmol, 1.5 equiv) was added as a solid in a single portion and the reaction mixture was stirred at rt for 18 h.
• reaction mixture was diluted with 30 mL of EtOAc and washed with three 20-mL portions of satd aq NaHC0 3 and 20 mL satd aq NaCl solution.
• the organic phase was dried over MgS0 4 , filtered and concentrated to afford a yellow oil.
• the organic phase was washed with three 20-mL portions of satd aq NaHCC>3 solution and 20 mL of satd aq aCl solution.
• the organic phase was dried of MgS0 4 , filtered, and concentrated to afford a yellow oil.
• the reaction mixture was diluted with 20 mL of EtOAc and washed with four 10-mL portions of 1 M aq NaOH solution until the aqueous washes no longer appeared yellow.
• the organic phase was washed with 20 mL of satd aq NaCl solution, dried over MgS0 4 , filtered, and concentrated to afford a white residue.
• a solution of this residue in 10 mL of 10% methanol in CH2CI2 was deposited onto 5 g of silica gel. The resulting free flowing powder was loaded on top of a 12 g column of silica gel and elution with 10%
• the yellow solution was stirred at rt for 20 h, at which point additional i-Pr 2 NEt (9.0 ⁇ , 0.005 mmol, 1 equiv) and DMAP (0.001 g, 0.01 mmol, 2 equiv) were added.
• the reaction mixture was stirred at rt for an additional 24 h.
• the reaction mixture was diluted with 10 mL of satd aq aHCOs solution and 10 mL of EtOAc.
• the organic phase was separated and washed sequentially with 10 mL of 1 M aq HC1 solution, 10 mL of 1 M aq NaOH solution, and 15 mL of satd aq NaCl solution.
• Step 1 Preparation of Cmpd 10a, 2-chloro-3 - ⁇ dispiro[adamantane-2,2'-[l,3,5]trioxolane-4', l "- cyclohexane] -4"-yl ⁇ -l, 4 -dihydronaphthalene -1 ,4 -dione
• reaction mixture was allowed to cool to rt and was diluted with 25 mL of EtOAc and 20 mL of H 2 0.
• the aqueous phase was separated and extracted with two 25 -mL portions of EtOAc and two 25 -mL portions of CHCI 3 .
• the combined organic phases were dried over Na 2 S0 4 , filtered, and concentrated to afford a yellow solid.
• a solution of this material in 10 mL of 10% MeOH/ CH2CI2 was deposited onto 5 g of silica gel. The resulting free flowing powder was loaded atop a column of 12 g of silica gel.
• a 10-mL microwave tube equipped with a stirbar and silicon cap was charged with chloroquinone Cmpd 10a (0.041 g, 0.1 mmol, 1.0 equiv) and methanol (4 mL).
• a solution of potassium hydroxide (0.200 g, 3.56 mmol, 40 equiv) in water (2 mL) was added dropwise via syringe over 2 min.
• the reaction mixture was heated in the microwave at 65 °C for 4 h. Due to insolubility of the starting material, the reaction mixture was transferred to a 50-mL recovery flask and diluted with 15 mL of THF.
• Step 1 Preparation of isocyanate Cmpd 11a, 5 -(3 -isocyanato-4-methoxyphenyl) -1 -(3,4,5 - trimethoxyphenyl) -lH-1, 2, 3 -triazole
• reaction mixture was stirred at rt for 15 minutes and then a solution of 2-adamantanone (1.049 g, 6.98 mmol, 1 equiv) dissolved in THF (10 mL) was added dropwise to the reaction mixture while stirring under Ar. After stirring for 2 hours the reaction mixture was diluted with CH2CI2 and washed with H 2 0. The aqueous layer was extracted with CH2CI2 and the organic phases were combined, washed with satd aq NaCl solution, dried over MgS0 4; filtered, and concentrated to a yellow oil which was purified via silica chromatography eluting with 100% hexanes to yield 0.680 g (66%) of Cmpd 12a as a fine white solid.
• Step 3 Preparation of dioxoiane Cmpd 12c, tert-butyl( ⁇ dispiro[adamantane-2,4'- [ 1,3] dioxoiane -2 ', 1 " -cyclohexane] -3 " -yloxy ⁇ )diphenylsilane

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Genetics & Genomics (AREA)
• Biotechnology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Immunology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Physics & Mathematics (AREA)
• Biophysics (AREA)
• Optics & Photonics (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Peptides Or Proteins (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Saccharide Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=53800676

Family Applications (1)

Country Status (5)

Cited By (2)

Families Citing this family (5)

Citations (18)